var title_f27_40_28288="PBC eruptive xanthomas on buttocks";
var content_f27_40_28288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PBC \"eruptive xanthomas\" on buttocks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Eruptive xanthomas\" from primary biliary cirrhosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28288=[""].join("\n");
var outline_f27_40_28288=null;
var title_f27_40_28289="AC joint cross body adduction test";
var content_f27_40_28289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AC joint cross body adduction test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain elicited by passively adducting the patient's arm, thereby compressing the acromioclavicular (AC) joint, is suggestive of AC pathology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28289=[""].join("\n");
var outline_f27_40_28289=null;
var title_f27_40_28290="Cystic pancreatic neuroendocrine tumor";
var content_f27_40_28290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of a contrast enhanced CT of the abdomen demonstrating a cystic pancreatic neuroendocrine tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28290=[""].join("\n");
var outline_f27_40_28290=null;
var title_f27_40_28291="Southern blot hybridization";
var content_f27_40_28291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Southern blotting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This representation shows the steps in Southern blotting.",
"    <br/>",
"    Step 1: Genomic DNA is digested by a restriction enzyme.",
"    <br/>",
"    Step 2: DNA is run on an agarose&nbsp;gel, giving a smeared appearance.",
"    <br/>",
"    Step 3: DNA is transferred from the gel to a membrane.",
"    <br/>",
"    Step 4: A radioactive probe is hybridized to the membrane and the membrane is exposed to X-ray film. The bands show the places where the probe hybridized to the patient DNA. If the DNA has a gene deletion or a mutation that eliminates a restriction enzyme site, then one or more bands may be missing. This step can also be performed using a non-radioactive probe.",
"    <br/>",
"    In the final image, normal individuals (Lanes 2 to 4) show the expected pattern, while an individual with a partial gene deletion (Lane 5) is missing one of the bands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28291=[""].join("\n");
var outline_f27_40_28291=null;
var title_f27_40_28292="Brimonidine: Patient drug information";
var content_f27_40_28292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brimonidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"     see \"Brimonidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=see_link\">",
"     see \"Brimonidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg; P",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine P&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine&reg;;",
"     </li>",
"     <li>",
"      PMS-Brimonidine Tartrate;",
"     </li>",
"     <li>",
"      ratio-Brimonidine;",
"     </li>",
"     <li>",
"      Sandoz-Brimonidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brimonidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11413 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-881851AA78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28292=[""].join("\n");
var outline_f27_40_28292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011641\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011643\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011642\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011647\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011648\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011650\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011645\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011646\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011651\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011652\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=related_link\">",
"      Brimonidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=related_link\">",
"      Brimonidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_40_28293="Retromembranous bleed 1";
var content_f27_40_28293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72314%7EOBGYN%2F51286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72314%7EOBGYN%2F51286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retromembranous bleed 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large retromembranous bleed is present posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retromembranous bleed 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADpAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD546Uveus0v4e+I9UHh82VtAw12KWWxLThQyxjL7j/AA49657+ytQ81IxYXjO4YxhYGPmAHBK4HzD3FAFQ0ZrU0HQb7XNZ/sy0WGG6Csz/AGuVbdIwvXcz4APbHWodc0m90PVrvTNUgMN5ayGOVMggEehHBGMc0AUeaWm5paADpS9sUn40ZoAD1paKSgApe/1pKOKAFzzR0opMUAGaPxrYvvDWs2OhWms3enzRabdHEU7YweuMjOVBwcEgbsHGcGscUBaxJbwzXMwitoZZpT0SJCzH8BzU93pt/Zor3ljeW6scBp4GjBPoCQK9G+Cni/QPA0Oq6jqb3cmrX7LZxi3jAa1t8HdKHPBOSPlHPFdH8QfG/hnxroF/pt94iv8A/Q7iO406Z7Rna42wbSrA42bn6n8aAPC+n1o4NWNPsrvUruK0soHnu5ASsMfJOOTiq7qyO6MpV0JVlYYKkdQR2NABmlptH0oAd3oJ496QdaOnvQAd6XqKSkzQA7pR1NJk/jRmgANJzS8UEhRkn2oAB14oz6VYvrO5sJlhvoJLeZkEipIu0lT0OKrdRQAvWjvR060CgBc0nPpRnuKAaAAGl+vSkozQAA0UfjRQAv6UHikpBQApyaSlHr0oJoAUdKKQ4ooA9o8GfFAWGgeHLCLw5dXUumwrawXKR+YzOGYyiMgHkqQMc4xk1u6Z8RrK81ER32natokWm2N5LJJI8jS+ZMgVVRypMZJztZuM8dK5rQNb0qf4feCdP1PxLZ2d1p2sGeaO2SSKW3tGGCuUQDceckEkhup6V02j/E3QryTWrzVdQe036lcT3Nn5RZtStGhMUMKnodmAfnwB1oA8+fxOmq/EOHxLLomrvCNi26ae+2dZY1AEnmBSHk4y3HOTXN+MtQvfEfibV9Xl0yS0eSffNAkTbYCeAG44J98ZJNe5aR4t8H6TaaZZ6ZqWm2tpH9taFEWZBGJIFWP7Qyjd5hbIZ4+ffvTB8RvClnfxXX9orPJcTWtterDE8gRYYWxKhcb5EEjKQzfvODmgD50u7W4s5vLvbea2k2htk0ZjbHrggce9JNbzwbPPhli3qHTzEK7lPRhnqPevQPEmpafLqHhqDxJ4mm8W2dpI73n2eA/JEz58tJZMSOT1IbAXOAasfHPxDonibX9K1DQLnzYRpsUMiCMxiJlJxHgk4IBGQMj3NAHmfejvRikGTzQApozRjFGBQAnWlxzR+tFAAK6b4d/2J/wlNt/wkez7LtbyvO/1HnY/d+djny89cfjxmuZooeo4vlaZ7neX2o2Ws3ya1ELlrgeVeWs4zHPHxheOMYwVK9MArjArzrxx4TGkqmqaO8lzoNw+1HbBktn6+VLj+LrhujAZGCCBreC/FUF7aQaD4lnESRjZYai//Lt6RSHvET0PVD7ZFdOjXOh31zZ39qkkUi+VdWc3McyHnBx26EMOnBB6GvKUp4OdpaxZ9vKlh+IMPzUko1oLb+unbseKbTjdg7c4zjij0r174h3FgnwvtbPSbAWOnRasiwxhg8jN5EheSR8Dcx47AAAAAYryrTWtkvQ16HaDGPlGSD616VOaqR5o7Hx+Jw08LUdGp8S3/M9H+E9rYWUYurhm/tKcEFj0iTsFNeg+KfBek+J4Gk1CP7NelAItTtly5PpKnAf6nn3rz7QLK2mZbizkHkxrub5hggdvXPtXUaZrN3p8suJmRVG/b1DegH+FWc55n4o8Aa34fV7jyRf6aOl5Z5dAP9tfvJ+Ix71yQ9a+k9M8TxtLbzTo9lKyn95EOME88CrWpaH4O8Tu66hp9r9qPIu7dvIklP8AtFeCfqDQB8xZ96XNez6h8F7V5GfTNckiiL4VbmEPtHuVIP04rBm+DfiLYfst3pNxLu2iIXJQ49csoA/OgDzXjNemaX4S8P8A/CMaRNq/9qJqF9C1yZbaVNsaGRlQGNl+bITd94feFVl+D3jBpTGttYFx2F9Gf611fiZEj1uSxtjvhsVjsIiv8SwqIwR9dufxrjxlaVKCcd2e/wAPZdTx9eUayvFL8eh5v438NweHLnTxaX73kF7bfaYzJB5LqvmOmGXcwHKHoTxXNMcDJ4HvX0b4n+Eya34maXUNYeK2tYYLZYreIEqscYVvmbjJYM2QCPmrT03wR4T8LsklpoJ1G9JzHLekzbfcA/KD+FdUL8q5tzxa/J7SXs/hu7enQ8A8NeDtc8Rp59haMllnBu5/ki/A9WPsua9M8M+ArHRGhmnBur3BP2qZPlT/AHEOQPqcn6V6rNLfahuMrRW8QAHJyPrxwKqapFFHD5WGnmC/Mw5Ge2KoyPHPH2lJq0JZMNdw/wCpbncx/u59DXlkiNHIySKUkQ7WU9VPpXu2sWd5Ky4jQEtsLE8LXnfjnQ1hX7ZbZaVCFmBGN49R6kUAcX+tBNKOgI6UdetACGlGKABjFHpQAD/PFFGTRwfagA/Cg0fhQRQAcZo7Zope9AFiysL2/MgsLS6uzGPnFvC0hX67QcV0138P9XtfBMfieaSzFq0aTNa+YfPjjdzGrsMbcFgRjdkelc5p2qahpZlOl397YtLgSG1neEvjpnaRmt278d65d+EV8N3M1vJpoVUZjCPOkRXLqrSdSAxJ9c96AOWIwaKU4J44ooA9oey8IWvw38KWurWthBqeuaYoimFsVmW4abaLh7jIARR1Q9fajxJ8KdA0RtW36lq80dnDZqNkI3GWaYxllBUeYmAGAX1xuPWsrwR4A0TxPpfh+b+1NTgmu7yO0maaNUjnZtxkjtgck+WACznKnPQGqer+C7O6s9GvfDGpXyW2oaw2hmLUmVmjmVgA4ZAAVIOegI96AO80/wCEmim71jRHkvGjivrcRTCFJbkh4iwDOEzAhOMhlO3v61zureF/DEOpfDG3ntmstN1BpYtSuWmVhIySlSGlUYzkAZGBg9utVpPh1Y6pc6zp3hPUtTbVdI1KHTbs3+1Yrh5GZN6bOUAZTwd3HftVOL4YCDw9r1/q+u2UUVnHFJZXEbO1rOrSMjsW2bgAyleF5PtzQB3+geE9Iu9Vgk8VeE7HS7uG/uY7CyhTy0vbVIXYPIhLeYoIGH4yT1PSvM/i5ZaRp58KRaLYi0W40WK9lO0bpWkZjuYjqeMe3aurtvhTpr2S30us3kVudEt9Q+RlnuEd32sfIUbzDjkEf0qDWPhroWn6Xe+IptR1WTw7ZQ5ZYnile4YybF8qcDy9vcqV3L0I70AeN+nNFeow+EPCI8N+LNVe48RTpovkyR/IlsZUmOEBR0JBU9TnDdRivLzxx19aAA0UZoFAB9KKM0UAHej60UfrQBNapFJdQx3ExhgZ1WSUJu2Lnlsd8DnFexat4k8GT2+n2drrV6llYW4trcGwaSUqCTl2ZhkkkkAcKOBgV4uadFG8zhIkZ3PICjJrOpSjVXLLY6sJjKuDqe1ou0vS/wCZ3/jjXtCvPCtrpOjXl1dS/bvtTyTWvkqgEZQAfMcnmuTgsbW4t3YSGKYNtEbty3uPasofNwKcSQ+eQ3TIqoQUI8sdjPEYipiajq1XeT3N7TrHU7C6JgkaE+mcBvr2ro9L8UyWk4TWYXypy00ShlOOmRXNWOqalpMcFxDcJcRP1Rhv247MD0rWtta0+a6E2pwTWcvZoPmjfPXK+n0qjE7GxvbG5YfYrq3Zn+9k4bJ9fSrEEbx4ZVZW3EbkA6fWuDudLNwzXWmSwz5OQkfyEfX1qnDqmo6TJHBK9xCc79pyQB6YPUUAevDVZdORWSSYIw25dse3SrWn+IJlhlt52DKn33YY+nPevO116/nt0luEiuLYN8hQ4b6Yq6fE9rHsM1hcIQdxGCRz/P8AGgD2ODWNH07TLLVmuWLSKzhWjZlM0fPlZXIznacnAww96888C2rah4w08OrS7JDcuuCS4jBkI987cfjVXw/4l0qUyaRqN1s0vUAq+a6kC2nziOT2AyQ3+yT6VfFno2gux1O/g1HVY+VsLO4xGp/6aTD/ANBTJ9xXnYqlVqVY2V0j67Jsbg8LgqvNLlm9O/R2aXz11+Z1N14iuY5ZvMSN5QdrB/lYZ9Qaqz+KJ0iCCFpdiYwDhQf61xHiPxLqetXIbU2BSECONY12iNeuF9vqSfU1nxazIk/yOHjxjPQZPrXonyTtfQ7C68R3buUVCit8qFckAe4pg1+5mdVLCGPIHC9SPf0qnYeK4WgjjvIlkKjGCvzEiuhtLmwnhaVrSNoWG4CPgrQI4/U764mndpJAfmwMA4B9cVzes3LtKnz7/K4PPc/XiutvIjeebLYWqm0ZirSEgH6Vy99CIbzbJE4c4JI4Cj2z1oA4PU7T7NOSo2oxyV6bD6VU9K6HWF8uabaqtHIn3fvsfTJ6CsCRGjO1uCB9aAG/SgUHtSnpQAnal/GjFFAAevXmkpaKAAUDFFFAAR3oq/pusalpdtfW2nX09tb3yeXdRxtgTL6N6jk1Q6AAAADpQAEUUUUAet58a23gbwvqn9uaclukccuj2sdp/pIw+1UV1hxkn+Ev83fNZP2Lxn438WNoOr3Q0++023kvvJuYPsyW6jDMyxxJnecg8Lk02TxJ4hTw54Hv/wCyNQi8OeH2iUSbpBa37pLvBbjaDkEZ5rN0zx7Lp3jPxF4kihfz9YhuokVbjabUzHIdHAySvbp+FAHcX938RNE8U6PPqlvJ4isLGa31AvZw7IrhnG2N5pBGrbxnrINwrP8AEVx8SLHxLr8LQy37b0tLuO3sVuLYAnzI4wpTbxuznAJPJqNfi1Pdwahbx6Gkur6pCkD3KzM8rybApYLtz820HapHOc5rorrxV4q1T+2dAn8Ca0Wu/wDSbi1tneOZY5AA24mNm2MyZGMY5HNAGTfad8SNNtI762v4n1B9Oitns7Mj7VDaAl0AwoDBSDkxsxXo2BWNBrHxLvr8X1ra6jKRbjMcOnIbdopCWBMQTYQxBOSOSM5rrtP8T+LdH0xZLb4eX0NlAG+1kpL5KIqMreUpUi3bB+ZhnJB45rnvEnxA1O3sLSyGgTaMoNheWQeVyRDAGCYyAWVwT81AHJa7rvitF1SLXprxRr6RTXQuowDcojZjIJGQoI424HGK5c4NdJ488Uy+LvE11qz26WaSKqR2qNuSBFGAqnA4zk8Ada5qgBcUUfjRQAfWiijigAozRRQAZ5qxbzJCFIRjKOQ4bGKrig0AXGksnbc0U0fsjDGfxqMLavy8kqjH3QuT+dRLHuVWyNpOD6irSWXmAmKQH2NAF8ajDCTGZjdWzoNytFtOfrnqPWsuOSJNgZXZCSXTPHtg0yeCSE/OOPUdKioA1tP1C2t5AGhmEOcnY+D9a7NNf0LULbE8lwsvTfNHnHGMZHavNqcjlCccZoA7EafpUm5be/VJF+cCM4APsD3qlcaXq9tFLIskjoDk4P3l7GuaJzz0+la+k+I9R0tnMU3mK8fl7JfmGP8AGgChc3MsjFZmZWUj5f6VYs2Q3OJ5vsykZXaMkVtNrulX9uE1KwAnfiSdANwHtVS5sBND9o09Y7yJPlyvBUdgfU0AWLXUTYwN+/juQ6f6osc/XPanLqdtMiqjGJwM7iuckdsf1qjNZ3XnlgkJeOPJQNwfp7/jVSYSIJDLEqOQCF24z+NAG1Feu8okyu0DIK+3Wt+y8QXEEuJJHCg8AHA59a4O1naMCGTIRn3464PtXWiMT2aXCMJBIRh+QBjr/wDqoA67w+0mpyzwwlXZzv8As5O1WA6kGs/XRJNaubBDhcg71zg98elZNlqjWMq7ATg5yv8AEfSugN7NrcAeEL5rDCQpwzH0+lAHm1/K0dwWlIKdhnk/hVC5bzAsb+Wig7l45Fa+vWhtJZEuIgtwzZIPb15HeqsOh6nqGkXWp2OnXUmn2bAT3IjOxCeBk/l+dAGPjrmjNTzLGbZTlRKvVfaq/wCFAC9qBRSE0AKKO9FFABRRRQAtB61e0zUjYW1/ALLT7r7WmzzLqASPD7xHPyHnrVAYAAyT9aADvRRRQB7Ronj/AML2/hrTYNcl1HVWjtYLKSzaLy5lRHJZHmXCSwdCEI3ds1OnjjwjZ3F5Pbx2U99ILON7ttJQJOBMTK6wldsZERC9AWIz714ccetL260Ae92vxC8AaRqcF7pOljyYZytpAlrsmst28SXIlPMm5WG2Mn5cdqwfC3ivQ/Dvi3w7JJ4k1bVdPsLe8WWaWApFG0qsFWKL745ILEkjPSvIsjpS96AOv8JfETX/AAxYWlrZSW7i2mlnQzJvbdIoVsnPIwOB2qh4z8Waj4x1SLUdZEJuo4Ft1aFdgKrnGR3PNc/7ZozQAnrS0dqKACjvRQelAB70n86X6UUAFP8AKfyfN2kx5xu96W3ha4l2JwANxJOABV7zpAqx2uYS2UaM9CvrQBnsMEcgg88dqRwoY7G3LngkYNXWtooo185/myVZMbSh+p4IqKG1aSdkZT8vOARkj29aAIYInnk8uFS74LYHoOpoE0m7erkNjGRRLGYnYckg9CMEfUUmxihcAlAfvDoKAJ57p5odjHJ4zkVW6Ug96U0ABBU4IIPvxRS5LH5jk470lAB0ooyBzW14e8O3etSK0YMdsesxGRQBimrukandaVeLc2UhR1PI6q31Fe2eGvhv4dEZOpWV7dyOh2eRKCA3YEVJq/wj0C0WI6hPc6YWwzKeTg+gzQB5ZPrWm6tEw1GKS1mZsmSDo31HpU2pW0l3axzW0cE6R4bzVYs3pg4qp4x8MNoMrzQSNNp7PiGVhgsPf3rE06/uNPkL20jJnkr2P1FAGpPZSSyO1vHKXjTLqOT7mp9MvjaqEV8wZy4HLL+mavJrEGtx+XFGbW9WMhiG+Rh7D+lYi/aIkaB4vIlxkoylMg/XnFAGzrF1512gt4gEZQQwwCxrf0z7dpek2OoR2kqwXTSRpOSMMynlQRzkZri9PuQ8iQzMNqgnOOh9jXskeq3mg+HPDVr5EMnmaWk8kV3EJAJGmldJMHjcARg+5BBBrKtVVGPNI7svwE8fV9jTetr6mRc+HbG5jttX8UNKm/EkVrGSs12Ox5/1cZ/vEZP8IPUXrHVtUv8AWLOPTraNkjVoYNPij/cCIjDoVPVSM7iTk9Se9VILW61mW61HULtYrZG33V/dMdiE+p6sx7KMk9hXMeM/FYGmyab4Vd7fS3+S6mYYuLv2cj7qf7CnHqWNeeva4uV9oo+pmsDkNJwaVStJa/P8l+LOf8dWGm6f4pvLfw7dLc2SsGTy38wREjLRh+jhSSoccEDPeuaIGBgn3q1a3Ato23Ju8znk9frVcsTuXAG7r716p8S3d3GCilxg/Xmk6UCFoPaijtQAGj6Un86PSgBfQ0Vf0240+C2vk1DTpbueRMW0qXJiFu394qFO/twSKoAYxzzQAfSijFFAH0FovinRrH4S6EkmoWBms9IJEJuUkdL1Zg0YNoQSzcf6wn5at+KvFfhuHR/FK6Vcad9rtrMjT5I5d7yyXgBuO5DYPXA+X2rlU8C6bJpOj6bp2hzX76npEV83iIXTRJbTuwB3EnyvKU8FQC57GmXHw2sNF0HxVeXE0uoeRpM01obiNreSCeGYRu+wMcxtn5Seo7CgC1HrOhf8KR+wfbdLKjS2h/s4oPtH9qecCJ8Y3Y2fx5x2rxK73NBIBjdtONteyeK/A2h6b8KRqtvZXEdzBY2N4mptMSt7LcMRJAF+78n+zyO9eM3bGO2d1OGA4NAH0Bf+KNC1Ox8IeDZjNqFtqWm2FvdNbss0Vky5LmONVLifgBjngHpSalo3hjwf8RvA9zeadp+m281pPLOVle4ginyywyEuSQAdpyRge+KPE/gnwkNVsvD+jmDS/EbrbXFq9tNM06J5PmTNMHOzccfuxGck4zisyLwRb/8ACxxa6xeap4g36E+sx215uhnupApKQSDczg+wOaAOT+Ml/Z6j4ns5LW6sr69TT4I9TvLMDy7i7AO91IADDG0bgO1cJXXfFXRLHw944vNP0uGWC2EMM/ku+827yRhmiyeflJxzz61yFAC80nPrS0UAIM04AswAHJ4puQOpxWnbWrxxESQOJnZWSUf8sx6EdwaAHadE9vdNHIga3lXbIeowe+e1PvNPNlMUM6vJE23KYZQD0PH8qsX9hette4glgkQhDGqlVB9Rn1qF0EcGSEkV1ILqcbR/tehFAC2sL3swiEiea5ChHPDntg/0NSxuILk29xbuDG2yaBxtKkdgf8Kr21tu2xsFMKDDzRE8+mR60Q7JYmIlP2hMuyzEkEDpg8gmgCtdrGzSS42qWOxWyWI9M+1NKJJHFhTGCcscjkfT+taLTvd2Qe5x5EaERyCMBt3o2OtVruOBlt5Le0eFmwuS+fm75+tAGY2AzbeVB4zSHIABz6itaSGCW3ULbTNeO23KHC5+nWqAjUzyRy7oyi4IxnBH1oAr9ewqRF4DEe9TpApILOuFXozY3ew96Ika4LMQ7qnyrtH6ZoAt6c1nHcJ5sQkHQhz+de+eCNJhl0NTpVpHFEhMr87ht9x7188xqFwGVVc8b26D3NbXh3xLqekSMNOllMirlk3khwPbuKAPqpNZn0prJQ1iZEw7RrFtOO3Of0rG8Yalp2pXw1Aj/SmwmWO5VI7kH+Qrzzwt8UtNunjTWtLjkRVyzIxGHP8AF749K7PQ9X8EahM05vpoLg5JEakHHr06+9AHNxqdU/tC0lgDRyRMQZYgo6dcnjFeA3MYhu5og6uEYjcpyOte4fFbxXoFvbSaf4fluZRMgDO6/OvqM+teGYAztzjtn+tACxs0civGxWRTkEdRW95sut2Sy+Yv9oW4KNGMLuT1P96uf9afE7RSrg8EjIB60ASzfLbAglZS3yg9h0Jr0u08a6RdaXp1vq2lXEs1naR2guLe+8suqLgMVaNgT64I/CuA1S3QKs1oFaJ+Ag+Yp65NV7SdLeZweUIx8w6H6HpUThGatJXN8PiauGnz0Zcr8j1DXda8O614NfS7Y6wt7BIbnTzLDGUR2wHUsH5BAB5XgjjqQfOmDyQvDcKZXHG4cbBU2+R42iRmDICAF4698+lVhMYIWhDbZD8r47j3NOEFBcsdia9eeIm6lR3b3M6VUViq7uOuf6VGCc1NP5ahVjYvjq2MVD35qjIXr1/OjHNT2Nnc30vlWcLSydMKOldDp/hGfUIJ4rZyb+JeIuD5j/3B6GgDl6Mk+tSTRSQTPFcRvFMhKujjDKw6gjsaiPvQAYpaKKADrQfar+mx6ZJa3x1O4vILlUzaJbwLIkjYPEhLKUHTkBqodvmxn2oAPpRRRQBYW/vUsGsFvLkWDNva2EreUW9SmduffFTz61qlw0jXGo3srSxCCQvOzb4x0Q5PKj0PFUPajvQBZN/dmyis2upzaRMXjgMhMaMepVc4BPqKqkbs5wc9aXsaKANXT9f1Gy1y31Yzfa7yDG1rweeCAMAHdzgDpzx2xU/iDxXrGva5Hq99dlL6IKsMlvmPyVXoqEHIA575561h0UASTzS3Ery3EryyOSzO7FixPUknqajpaSgAxRS113wy8E3XjXX44THKmj27g3lwFO31EQP95vboKAN74T+BJNSiHiXVrUS6XE4S2t2ODOTwZMf3V7ZGDXssemaI99DbSaMvkhguCuDn1Hp9Pyrr10yGCa2XS0isZbSMLDbKuyN4R0CN0yPQ11R0vTtUeK6ihilzgSuw2uO4Ixj5gaAOI/seJF/s82FhPAuSLiaPeUHUKSOcfhxWBq3wf0HUYp5tv2G5nj8xfs6ny0J7MOwPrXsNxaxR38kkkaOk4AMZPDEd+eAamt7G3tl8uGOQQ/eXBzt/2fXHtzQB86a18HtUnW20/THQLGo3s0IViv16OPpzXIeIvhD4xsX+yppcdzDLzILQg5UfxL6EdxX2ABGkokZVjGCBzya5HxnDdtCNS0eS4MiA5MHGB33DPWgD441TQb7Qbya11SwuobOFMgvEcuT3z0BqGe10wCR7K6F2jRBgxG1ix7FfUeor628Pa1rE1nI2raO+p6ewxLLJGoZfz+8K8i+K/wAMvs8914i8H2pt4ZAJJbNfmMYH3mGM4B9KAPIbeaKylhuYAJpABuiYnP1PfFQ3PmXty4VUhbfveRjgJn+EA84qaPy55ZpZITCQpXcWwG9hjqfY1FELVoIVvpZJVwVjwmec/dycUANhljt5rhZbcSyhSjSPjZg9wOmfei1FqthdI8IEhZRDIkmCp9x3p1xFEdTigjeeWBcDbJHtkjPpgHkVN9ljkuZidsceATzu8z2PpQAniW61HULmFtShEbWsaxJ+7CALjj6/Wo9P0a/1q6ggsD585wg8tfmx6enH1qe106XUruOCKMyozYEYU5Az19T+lfQ+h6XB4H0iCws4xJqVwvzvIhwFPboCD9KAOO8PfDnRbGKGbVJRqN6p2y2kClGiHqezH6V7Va6P4UstMjVrXSUKKPLWVCH6dGHc1y+mWEtnam9tbxbi/jkyTjdt9fXpV1raWezfUoY1IiOJg4JXk9Qy9M/lQBzl78OvCnid3kuIH0sFyvnKw2s3Yk9ifQ153rvwQ1mKOWfSIjdRg4jRTnePUV6lZ2Da5qrpbOIzHk/OxAjx3wOtabS3dhNC1ldBL+Vcb43wHUHoQfWgD5J1bR7/AEZpINStjDMGwQx+ZPbFZ4C7SWbvgL3NfYfi/RdM8d2LwzWMVvqyJ+8nUgqr44ycck+lfLfiXw/eaDcy29zCyOSV3OuC2O6+lAFXR7yKOK5tjA0pnXarMciI+o96guLdFbJkjO0DIjbv755zVFmdNwViueuDjNdRb2AvdJhedlhYtu5wu/HrQBS04JcWsrsyx+WfvdS1Z0zxb22O7BuXz/EaW6kuIC8DbVjJwFXofx71WYbnAUfiOlADGwTwCM9B1rsPBfg1dVJvdcm+yaZHyYwf3svtjsD+dcvZkwzRSBVzvxlu/wBK9A0K9hnAjg8yRVPzHPBPuxoA7ux0W0kg/wCJdHHp+mxDCqi/PJ9T/QfnUem/2VpGrJdGMeeuTGD0THVsDqaw9Q1F/IKPK6mIcMGxx6DuawrrxSYozJFsH8AbGSPYZ6+5oAZ8T7SLU5pfEVnGwlkfF3EExn/pp9fWvO+CMg5B6Guwh8SOkBSWRZHOQgIyoz1J7E1y99bpbTKIXDxONwK9Ae4HtQBWpe1FFABxRWt4f0/S79rgaxri6OEx5ZazkuPMz14Tpj3rurrQfDS/BtdUt4UXVYpljN5cS/PeZkIzCiyfKAoGVeMEDvQB5f0FFK+M/KeKKAENHeg96BQAYpaKKAAUGiigA60YoIpUR5JEjhjaWWRgiRoMs7HoAPU0AXtC0e+17VItP0yF5JpOXdVyIY/4pG9FAr7D+HOi6ZoHgyLSLSOKO5swXeUHab1W6y57n2OcYrzn4UeEYPC1sBqUrWmuXK5uZsfNAp6Re6jv616XoO1LqKykRV+yucoeYpVP90n7ufTigDY0q7N01zDHdYjEeGhbHP8AtLnpn2/Kuh09oi8crzQlwMZibG//AHk9fcVyFvN5mrpKJTHAJDEnmqNwB/gJ6H8a22t4FvpGika1jtzuwyg/l3/I0AbEjpcs/wBmdHkZSWQyYXcOgIqQRtdW8Mkwlgu4eQsZztPT6MKp2TWoWa8KJ+/IAL5wW9TnoD60xLm5F0IF8pZIssN0mAB/d+n5/WgDVlukCokpVZm+6HUgMfx6UbJJ4pmVPKmdNnznK59SKxY75L0yzbrkFWHmJHJkLjuFrWnmURxIsm2SYbvORMrkf3vSgCJbR7Kz+aZvKVcFI1wM+vtVTVIIpbFIhP5bvk7gu0SIeobqDWqlqgkXY+Nwyygkqw79aWC2SDckZJtiMCM8qh/nQB4L4s+Bou7iefwleWrKwJNvcrlAx9DXiOv6BrGhXDaffWTpdWxzIqjp/tA46V9rxxyQ6XcpbkQ3W8kAqOOfQ54rhfHvg0+IZBHH5S380JLKGyHI/unIx9DQB8o3+ojV7u3nNukVxDH5aNEuxiR/eI4NLcSW8dpuuIZUugw3AHCr/jmr2u6Le+FrsWuqxqJoZtzK6YIXPYg4YVe8MaYvie/e0igGZZgwl3FD9Np4FAHp3wH0q0Yy6xdQPG0PyrIxwgc9M57V6rb2PniX+0iqtI243B+8o/vBT29xVO30i20vR4NCgVrJXx9puJZCOR02gHp79KuX0B054HiRZ4YU2by/zTKOx+tAGHqdyIoPstnAsd2ZmC3W0qWj/wBrHrTNOF2IZJXKQxFgplMgCSY7J3J9uata3eWlrarrF2JbC0uG2hQoDIB1XHv61k31xDcabG+lSwNZSMWiG5t+7+hoAS+MKoGimDNvMZEeGdR33dD+JqWSFI7Ty7SxnVRguqLnJ9cD/Gq+jz3tolxAn2dkkAMrFiNv1Azk1s6JfyDU1lgbzZWyr+d8qH6AHOPyoAy9XkeO3jgSa5gkkZZSVUoqnt8vf8qreOvC3/CaeFl1SWRri8t0KkkbTkeo/wD1V0+pQtq94ZmsbbCrsDW4++O5ORx+tZtpcxaAIr2wuGuLeR/Jki2bivtyQCfwoA+UtTs2stSEciYwcbx2NNtmecv8hG5tqsSeD64716V8Z9P0+x8QteRWskVu3zbWcbyx55xwPwrz/TJi0rTOjAdAuegoAZq9skMUL+VLJK/ys8pyPooFZl4whCLE/mKOevC/gK3dVukntwlyxHl9FVtpA/GsuGGKSByieTExGO5b6GgCgIpZCOHMnXBGABXX6G5tLdTNJFEkZyhPX8qwRDtkAUsoJySOeP6mq0zL50m6Qsy9A54xQB1N9qLXczLa73UtuMpACn8+1ZGrukiguhmmIwscf3QPUn0rP+37kRFxGijGTyWP0pl3ePJGsR8xAerNwW/CgCofMkn2A73zj5elXF053djLKiKq7ndjwo/z2pLSdkVYLZVQOfnkx8x9hWlcW7GJVZU2IwZ1zkE+nuaAMG4heFgrAgMNyEjG5fWo+1dDrvlSwxwwxEuvzvO/Dk+mOw9q59hg4IIPoaAE/CjAznAz61oabpc2oWl9cRXNjClmm90uLlInkHpGrHLnjoKz1OecfnQAvail/CigBPwooNLjHegAA96KKKAEpe9FHWgBCQASxwBySa9i+C3hFrUL4o1a2BZkP9nxSJnyz/z2I7H04Irkvhf4QXxNrUc+qK8ehwP+8cr8s7jpHn09TX0LLiOzigjmSAxnClhtUL/dBHGKANbS7qG5uds9rm5uFyWUBg3vg/qK1zbQGCKOOcLJnYdylTC3pn09jXK2lwNhsoollR1OxxlXjb2x+mMirUt/f2+nWi3l2DPG+Vu1H7zA7E/xfQ0AdbazvbTyre6eyypGBKsTKVnTs2DwfrxVqz1bTbOGMu7xSPL5bCVTnaem5fSuS1DxRLqN4lhaNE77AxCJ8rN6juh/SpIdOupLnfcJNGIRtMEyhkkB7BugP1oA0NV1KXN1aab5ynlk8kZSUHug7VgWGpSx2IFzK80SP86yxnfEa1bizuHkthpy3K2MDEtDKuPKPcBv61ftdCgv1lS/N0XkGIpIpAQw/un3FAFXwxNJHdztFMs0LkFACUbB67Qf/riumNxPFfXMUcUk4MYwX4J9QeMA+xH0rgrfRruw1OfTra4E8a5aPzRiQH+6R/hWxpXiyG3H2XUYngvUzGk0iljGfQnGSKAO1a5+x6fF5qqj5CRBj0zTntoRc/aC7LKgy4ZiR9a5oXYSWO4uAJ5WbD7WJ5HQ7TyPwrSeZ4bu3nlt5ZPOwplHAA9COuaANSC7W6aUwmOTadq7h8wPuR2qZoY45RMI4cgfMxwCuPTiq0xVpY7aO5ZJgS4YJ/D71YcM/lxi4BcMDl1HI+lAHm/xX8JWvjNE8qb/AExImMOcBDjtkdc1478NfDpg8RS/anMU1n90bTnd747V9I6mwS5kjhnjt2UgMyAswB7EAcA1w3ivTra1eW+0aQCGZfKnTdgxt6r3oAqWTzr4hkmuLjCBcsFbdn86v6yv9rb3tGdJEAJbIBP1BJA/Cuc0aW0024Tzrj7asi43tyU+oBxU966StG6XpjhBKklz8w7Y6GgB9yLJofI1dpri0BAlhjfbu+matWdpBHLbusKx2gOLWB/ugf3mI6mmWkNqIyly8ssQXdkAtuP41qGWG10lLqAW7QzgrHblSzL9B0WgCvO0MvnSJIApB3psOxj2OcfpR4f+zS6WwVd8+/J3PsIHpj0qGyuUuNNIurWZSj/u1C7VX/ez2qpYSQW+ozfbMzMwynluF/xoA6Oe/e3jh82K1EIbDJbSgMPYsMYH51n3yTXqXFrYRb/N4X7ImAH7AufT2qSLUdOtgH/s271C43ZSOSVVjjPtiucn1nU7wzxGV7CDcX8hBnJ/3jQBwPxQ0CXTLOSO+YyXQIMrmXzMf0FcP4cgtY7eSWJMCJCfMl+bBPoDXZ+KUn1mV9NgcyOx5mckqPp6n3rPfTo9MjW1tSGcYEkjDYqn1yaAOB1tl8wJFbyqGbJMoyXP+HtTrYqobei+Yg+QEcCui1mBREzxiGWVesmS2T6k/wCFYdvCjMzcPGMYKnPPsCcUAQXr5hZ5I2iwOFHf8e1YpYkcnrXS+IIGFsFVxsODhjXNEZXIxgH8TQAiMUbcpwR0I7VZs4munO8s/r6/maqjGcVYa5byvKjwqdOOtAEtpcpaTSuI97DKrk5C/wCfWnf2ncCMbdqnsR/D9P8AGqKY6Yyx4FSzQGEAuQGb+DPP1PpQA5LqRXjZzvCndg9/qabeXEl5dPcTbfMfrtGBxUNFACfWir2n6TqOo215cafY3N1BZLvuZIYyywr1y5H3RwevpVIHPIOe9AHonwQ8BweOfFFxBqsoi0m1t2eTZMEkeQg7Avc4wSe2BRWr+zPNokPj+ZtalaK6FpIbOUyhI1BUiRWyOSVOQc9qKTjcDyagCjuaKYB2pe9HFBoATvV7Q9Lm1rVIrCBvLDfNLNjIhTux/oKpokkkiRQoZJZDtRB/EfSvR9CistE0CFT5Mk7zFpbyM7ZA/wDcPXAHTHHvQB6J4e8nT/DKWOlon2a3ONn8LH/npnqrH8jWm2ove6PLBMogmU7Hkxz7E4/n/OvPNP1kNJI9owjdeJIzwre/t+HHtVs6kL698hVf7eq7fKDbHkT1U9Gx6UAdJZalcQ2sOnmTzHWT92SdhB9Pr+VaOoyTQ3G7UHE0UoG4ngg+/wD9cVytnHeiZo5dz7uFLKCw9AwrZ0n7Re3ELTh5EiysischB+PQfXigDrdNtYVMF7ayxusf7uQKxzGh7564ra0zV59PuZLEhLpI8lLhSWVkPY+v0PHoawdF05Le6klsiok52AsURv8AZ9KvxyXK4jj05Y5y24sreW8bD27g0Ab2naorx3FnDMyxyncsZbIP+63PHsat+JZpLW0tRZCUE/eVSd6n2/8ArE1zFtYR3uoLJbr5d9nlEPIb3HcfrWneSai9rNHL5H9oWo3vDI3LKO4B5xQBsaTpw17yb+a5khuogULquQx7Ek9xV3XUubTRBHevDcS5A80Qkn8T2+tR+FdXTXrGKezf7NdhdrjYGBx2PfFWhc3kmoOxEUdwimM/MSrD129R+tAGFI8guYILoSRQiMs5kUOr+m09voDTtJ1EOg8iORp/uhWYhnX/AGT61uTada4Fxq86K0hHDEBSR0weB/KuQ19YrTXYTY2BgvJOVT5ZIph+ByDQB0cF1LBeLII7xrIk/OSDJE2OQy9f51t2QiitllgkJV2+Z1UsxHbOeRXnU91el44JNSUpHJuktbiErKh9FJzkfjXe2txDNaG8sRIkhH3iB83rkdaAHoFY3PnymOSP5lnjXaSvo3GD+Ncj43t7drO3KrFLJICwaFwrE+pI7e1dbaXD3SyG5MnlYIWQKULexGOa4vxvZynT3kW5Zto+UE4/DA/+tQBwGmkQX3lzISRwXT+H6jjmna7qsOkSR3NkkcrN8qwzAMU/2j2qtpM7NdNE8jvK3PPzcd8f/Xq5rfhsS3UVy91Iit8ySSoEUY7ZxwaANPQtVmktk+0TLNLM4aTKgFF9FyB+laOpSQ2MXzQmLzXyr5+bb7J0/Gnae6f2bbsYI5dRVsO+QCV9cEAfrVHURY3OoRxzvOMcMJcE59sdqAKLXyx2VyGeeVOiLINuM+wNQaTJo0MiNO0jAYLEup2n8+Pxp+qC0jLxWDzTBvl3EgIntg1gW9nHBNN58ny5GBgbR74wSfxoA9ZuPFGgz2Cb9PiWGIgjeo3MR0xtrB8b+IdN1nTIorO0t1ulO53zsAH4DpVjwgfDGlzRTXDPc3QGRtiyob1wa5v4ja3ZS6i13psCiQ8MWAYL9B0oA841bVDBP5kk8Y2ngJgKPfmsa6dnyZJd0f322NnI9ST0/AU7xI4upY0IeRmO4AptCe/PWqn9p2Ol/u3+Z9uA2C+fwoAzNVvVeJra0RQjdWXJLfie9V9Jt1eNF3LEgbBebg49PU/hiq2rXNzeXDzMyJEeEjQgcfQd66zwz4I1y70qC/g0+5NrMu+KUsoDj2JIGPegaTbsjD8SCCAAQMWAXG8gruPsOuK5dQWYKASx6D1r0PXPA/iGO2vNQksY2trSPzJ2a/tz5S9Om/J54wB14rgVdhKGjwCOBjjHvSTT2HKLi7SVgnh8oKGZS/cA5xUNSSDnLMWY9TUdMkdE7Rg7Dgnv3FNOTnnJopaADH0pV2lgHJC98DJpKAvT3oAs26vI7CImOHHzktgY9/X6VXcKGYRklc8E8EinEYwGPXnrSFsrtwAM546mgBhGeCAaKWigBDS0hpaAAUhIAJJ/GnA816F8IPCEOu3suraqqHTrT/UQyghbqX6+g/U0Ac9Y6TNZWcN5KAt255gdcmND6j1PXjmmS+bb3wkt9i+b/rI3bKSe4Pf+deu+I9GtLq989ZfLMgwwkGCjdg3Yj0Nczc+FYtUWSOTMEqMA6EYD+49/cdaAOb0y0uZJZJ4NyKvyvhc8e47ityBriLUYZZoUmgTH7yH+EeozyPpUmk6JPZG4gineYRDO4feA9x/Wuz03TH1Sxt5isTbGyzxkLvHcHHRvyzQA21sLnWVLSQ3Msef3V5ECHA/uuOn5102j+Ebq0mSUzNJFKpyzggH1yRyp/Ot3S7c6fALnTZbkIg2PLCuZIh/tDqcejAg9jVlLiS58y6kuUcp8ryWp2Pns+w4B98Y+lAGTZaIILqVX1SS2kblUbDK+P0P+eK3jpks0MMl/eoYn+SGQfMAfQgcqa5W5uJraS4E0cVzC/KtKpCt7j0P0NRxeIJbryIb+IPbIMxsSVYD/AGZBz+BoA0fEGn6pohhnaeSSNz8k687T2HP8qpJ4h1K5VzqkaXKsAgdzhoz6g9R9K2NMu7G/R7fU5JHTdiGUHLL7MOh+tWobGxt7p5Guo7mfGHcfI2PQr3/WgDDl0i80qxNxBPeWrD5wdpQMfYjofrWlYnxBq7DUYbqQ3EAGwsMb8dvr9ODXT2PiC1igS3muGfyxhUaM4dfrng/Sqn9swI+2GKWKMkklCCB78cfpQA6Pxfa3Vg1vrkErTt8pAUAr61zWuw2UJtLq1GZY2Djy5Ny49OOh/KtjVFv9SjkUR2906fMcR7ZGHYkd/qK52YtNL5aw7JoxlwqnBHuOM/nQBNe6bqeuzS3KSCZGAaMyOd4x2BBP611PhqS5itlN2Z7cwD5SSJRn9DXCQ6fbXN61417PFLGMqsKlsH3XIOPzrpfDl3LJFOknk3Mb/ejPAYDv1yD+NAHR37q1k6RBj5sm9jIuMN6jPIFcX4mhZ45GnePMbZIQ/ePqcHJrtbi7kSzR7eyt4YUX72/DAe6t1rh/FWqWV5bI1qxhcH94FjCqf8/WgDhvFF+/kxTJMQ8JBUrhhge2Aa7Dwz4/h1vRUtL65icYwweMYP1rk9dt1urKVY4gFRcswUB3H58/jSeG9H8OwaepgtZppRgyxy5XP0PSgD0fy9OkSB7C4mEoyHifDR49scioL+xZF8yGIXcsRzuh+X8Oa5m9vZbA/a9Hsbi2syMDy2wvHqx/pRaeP4J5PL1C6+yOAPmf94WH17UAU5ZJLi6X7Pp8v2uRv9USdo+gpNU0rUFhQG3VJHbOPLYkfrXZ6R4u0CNpZP8AhJrK3dusohLv9ASK848a+LdKmu7iHS9XutQk3fKfL2ge/JxQBDKfsk5e9Z5bjpgy4B9tqiuV8RSPJIfKXy9w3eUjEn9Oawr28li82Z3ZTu+XzX7+oA61nTai9zBIHaSJmGQ6gJvx7D/GgDqoYNI0yI3ep3l3NMy4EaY/melctJnV72Zo5IbOBjwXYkkemByax2uLi5Ox2kkY8EZyT/8AWrp9B0+W7USvCixxjAwCD+HOTQBRbQ0Rl3TyzY67Y8D9TXod7HjRPDRj+ZP7Htzkc4xlT+oIqta6bJJASu+SId9mMfhXVReJ7600jT4NOskgghi8mdinmG7AZyEYdNmHPHvnPTHPiaPtoct7HqZRmKy6v7Zxvpa33GA0MWv+Gm8PtdfYLkzG4gl3bYbiTGAk57Ac7W6KWORg5HmN1psuh6rc2mpI8V9bko0RUghv89+9eualpcF9Zy6pokTpFHzdWRyzWv8AtA/xR+/Vejdia6NZ+IbSDTdckMM8QCWeoIvzxjtHIcZaP9V7ZHFcmHrug/Y1fkz380yynmdN5hgXdvddf+H8vuPGzExVpZcIpP3R1P0H+NQVq+JtPudK1y9sb2ExXVvK0cqbw+1hxgEcH8Kya9M+MAUvag8UZ9KADrS5AGAOe5p0YAyXH0ppPyjgigC/p2s6lptpfWun3s1vbXyeXdRxnAmX0b25NUANoAA46YppODgkCl/nQAvrRSUUABo9KT1oHWgBHAZSDkAjBwa77wZ42+wW8NhfusEcS7IJ0UBAvZXX+v51wfaigD2nUNWSeDEW0TLyIj0YHrt9vamWWuzqihVxbn7jfeCn+76j6V5XpWs3GnhYmUXNmD/qHP3f909q7zRLu3v7aUabdK8LDLRTDEkJ9G9R79KAO/0i9sNQtyzKYL+HmOaIfdPocc4rdilaG1WeW3S3kmPEiptSX8QNp/GvOLKO8sczSpIQp5lh6geuf8a9H8O69pk+hNp+qXb20dww2TOmYJG9/wDnm/uDzQBb0rxDb2qMl9cL5QBTcPkkjz/Cw7r6EdKmuNUs71BAsTG4UfurqMYZx/cfH3vrVe98I3GnMLi2t4dVsussUY3MB6gdQazEs7TUp5RpN0scSDPlS/KyH2PY0AaL61BdabJp+2RIk5JkUNtPqD6UlqbYRiGERxxSjBIO6Fm9Rn7p/KuZ06LUYb6cOXughziT735960dG1KC4lnhW1eCYEH7wCn8DQBegimRXgFmWuAeAGwcezD+tO8yRrqIS2xLoM/OwVzj36Grki2/mvKq3FrLGM+ZGuUf6r2+orOc211M5SWU7uWx8yn6qf5igDQv5ZI9s1vNHA0n+sC5ZcfQ5qXTtWafTpbSby52VvlMeEY+2P/1iorK/ltLRrd4Wkty2EHADH6Hp+BFWEe1eDyrnTUidTuVZUG9foxAyPxoA07mWa2ih+xyNcSKAVtp0+dP91wf0qhfG6lvUuJo/JaT7okbCk/7wo6XCsxuo3P3QwyhH9K1LuKS8smgtoCXK5kj34De+O596AMO/RUmAngtorhRjdBMdn16/0o06D7FN58kLNkcgDse/HUe+KpXdu9lbpNd5TbwNx3Y9sUtvqNqtxG9uTGWGQWGVJ9cE8UAb+pXsaRRASFpgMcfKceh9fwrl7uBZGkad2jCjIA5H0xmtS71TynaS7iLKUwrRxjDe+K5nV53+yJLkbAc4A/T0oAzPEUkbacs0kcsZjOAxACsKl0TV0j02W3ks3YyDKyJxiquoRC5tdhUwWsy4MqgMB65qXRooNJsI2g1NrqPBBgZsD8aANxLGPUtHEaX00e1cnfyv868d8U6Lcf2t5dqz3LjlnjXK4/DNeleIvEtlb2AZdOe3tyvzN5hZZD6e1cJJ49s4rR/7Otporhm4THyqPrnNAFWx8P3K2wm1O6a3iPy4C4yPakkstHtVMkKCWVfbg/pzVB9Qn1FZLhpCzrydrDC/nWI1/Cu4I9zICctvwMn8OgoAsaqWCF5tsbn7q5OMemBWTM7yhBhcAYCrzSTXDTsS+fZc8AVYssyORbwyFz18sZI/GgCbRtPe5uwsgKDpy2z9a9E0sPp8A2pHHHkIGJLO/sB2rD8NaSTfJLdWwBjGQz5JP48V2KLIJ1ezdJ3X7qoown86ANuPTdgjluXkjhPO0knd+BqtrN9bW0RSOdcHgKpxj8v8a57U9Q1GeZDcSGQqMEZJIHp7ViNbSyyM8jpEmeEGP8mgDdstfl0+4S40oStcqcKydM+h9R6g8GptZ8WadpFlJqenWDWfiCT92sXBgtm7yxck7jxtU8IcnJ4xlxWzJEgiZwp5wTgfXjmuV8TxRksyJjBwZZ+p/wB0VEqcZtOS2Oijiq1CMo0pNKSs/M5uaV5pXd2ZmYliWOST9ajoz6frS/pVnOFA4FJ/OgUAO/Gk+lGDR0oAv6bqt1ptrf29qLfy75BHN5tvHK2MH7rMpKHnqpBqgOgHoMUc1NBa3M6hoLeeVS4jBjjLAuei8d/brQBD+dFPljkhkeOZHjlQ7WR1Ksp9CD0ooAiNLQetBoAUUUlFABT4ZZIJkmt5HilX7skZww/GmA9jS0AeieEPiAtuFtdbDRqeBeQD7nuyenrjP0r0Wwe11HRpTLLBJayH5LmAgq3sw/rXzt+lXNN1O90wv9guHiV/vx9Uf/eXofr1oA+lfD0OqWHk3Gg6o8saDAVDuZP9ko39KzNf8UWepXT/AGy0jttahb5ry0UgSDvvjPf1xXnfhLxxapJGuoSSWE/QyJzHn1z2+h/OuwvNTgvc/bFhuB1S6jBVvrkfzFAGnZ3+o3KwPY6hbO4yo28kj0Gf5VXvLTUIZmMhjMrfMcEDn/aU9veueu1ktWE7Fo2U5V1XqOxPrWqfED3WnKL0pLJEQVkPUf5+tADTeXzARGV7dw3RHJXP64rRe5vTEFPlyE8OeMn8u/4VmazexyRwXcaqARgkHdz9eo/Go7XxJ5eQhRgwwVdQ4PuCeQfxoA6q3mm+RYo2jfHLZwD747/hWvJKzWah7yWNc8x/6xSfUHGR9K5vQteMl2IkKqR0BGV+oGeK7m30211122uLa66OFBGffn/GgBlvd3Wn6erqtrdIw/1nKutakekfabEalZRKRszIoHzD3B/pmmweA7nyyIdRguYm52MCrD+f9KvwaNfadEbWeUrC+E2HcI2/EcA0ActLps19GIX8y4lflURjnH55/Ssm70jT7PzPJys4HMc2Tz6YNdvrWkyaeqgQWnlr8wdhmQe28f4VlLJp6wvNeYd2GMPk5P1oA49Z/NsWRpGlRDgow3bfp6VRv7mN1Edwd0QAwAgOPqM10FwlpexzP56beiqJSNv6c1gXtkRGscjCaL13cn+RNAHIa/4hfSbdzaQRgHsYxj61wuoeKtUvfnLQwbuP3YxmvW20DT79mhudwbG5Q5KnHtWJc/D7THkdYHZHPJDcgfXigDyW7vbm6AS4ld1XoGOeaijKAnfuz22nFe1r8OPDNjo51KU3mstEAbm2hnFssBJx8xwWZckcrj3NO0LTNB1t5/D8WgaXYJfQvFbzqrSTxzY3RkSyFmGWUKQMA7jxWE8TCE1B7s9PD5RicTQliKaXKr9V08tzxQykqVjBGT65J+tNWORs7UYjvgV2knhe0gMTxNJJkAhmAKn8OtX2sb6AKqQxBGGAB8ij3rc8w4aKwlMYeRXBJ+7iuv8ACtkIhn7MWZR94McD8O5qWdl09T5ktuJSvAaTJz9AKwrq9liuV8ksZWwQsRIXPv3oA9C1RIraFJpoY1UjGbhgQf8AgIrLXU4YYwtmHllB5MIKD8q564bVDELm8ZEVeSGYLj6DvVSz1GWQsxWRc9BjAagDde6kupCsIcEHnPOf8+tbljZQJatNIJJWPYDI/liuc0KaWVyRCkTbvvklz+XStTxBfzxJGLi6Lg8BQQP5UAJrGoSW6YhjSPPbdub/AOtXn2s3b3V2xc8LWprOqQNAYYYXyerH5Rn8eT+lc2DxQAtAozRmgBeKTNFH1oAU0lFFAGt4f1Ox0x7g6hollrAkxsW6lmjEWOu3y3XOffNehfD74i6ToHhtLHUIL1JU1OW7gjtYw0drG8TR/IzMGLAtnnnjrXk9FAHVfErxDb+KPGN7qtiJ0t5Y4YlE4AkfZGFLtgnliM9T9aK5WigBDQP5UHrR9aAF/nSUUvHagApc5pvvRQAvtR09aO3NJQAtWtP1G709ibSdkU/eQ/MjfVTx/Wqnel4oA7K18YidUh1CJo4lHBjYkKfp1FNvNVtxE4jcNE465PP5cVx1LmgDpdM8SSWls0QUOvYt1FVotSkmlZo4wjMcuEY5PvWH2pyO0bB42KsOhFAHa6HrDw3bIsgQjkCRsH9a9s8DeI55bVra6SPYOAZThvopr5uOqTO6+awkX1YZI/H0rrNC1veqxRq4jHofun8KAPqzQNVtbWUTSySsxG1AyZYe2R1FWdQ137WwktJLm0YcOWUlD+FeWeBNVs3dG1JnZ05jZJduPzr0y21Rba6ee83RWsy5XzEEqye5AOaAMzUNTlWRDqMayo3WW32nI98Gkv8AWNDuUSExbFI/1kaYH0IPeqtxfwXEkn2BUeRWy2xG5H+6ciq84tHia5vbePyxyVBCOPzoAq3ml6QU82yvbWRD1XO1lPuBisW98Mwb1lX5sjkRz7/x9aV20/7QwtxIUflN+G21YgfTLX5Z/N87qM4Ix+HIoAqQaaIWMc1pPKvZzktj8ao3K2UVw3lmSGQcZGc/jzXc6Pqmj2/76Jsp0cxzFW/ImrGpX/hVrG/uZNLMkdrH5zOz8tyAq/8AAmIH40m1FXZdOEqklCCu3ojy7xRINL0tNNSXfdXu25um2kFY+sUZyT6lz9U9KZolpYaZplrqeqi+F1cS+ZZm0I3xKh/1pB4bLjAGR9xuRxWdYQ3PinxMTdTBXuJGmuJscRoMs7Y9AAcD6CvVL+48P6gII7bT7k+VEscaAjCqowMnBry6EPrNV1Z7dD7TM8R/Y2Dp4Kg7Terf5/e9PRWPL/ElzZP4gvZNHhh+zyStLH5qmM/MdxGD0wSRWFfedchnZvnHCrGxIH44r0/WvCxELXUUUjjHovA/MV5XrFrJ5ssMChiOpRju+h7CvVPiDnNQVrWTdKyvMf7z7sD+lYqyyPLuUkNn+EZP51YvIjbyMZbaSEA/e37y38hVG4lR4zIIjwcAngUAaV1u2JvkAc9N5LN+QNRWaxLIJJpQjg8lhz+VUzeSsmyGJQB1KjpVvTANgEhBBPLckigDrE1O2gMSxwtJxnLKM/gormPEeuPqN0VWMQInGQo3fpWlNqVvplg8cNvEZnH+skTLH9a49mLMWONxOTjigAdmdtzksfUnNIKDRQAtH0pBzS0AFH6Ud6KACiiigC9praWLW+/tRL97koPsZtnRUVv+moYEkdPu4qiMgc9aKO9ABRRRQAhoyKGooAP5UUCjtQAelBope9ACUUq0nagApaOxo/woAKM9qQ/1oPWgAopTR2oAM1b0/UJrGQtEEbPZwf6VTHSg0AdronjSK0lVrm3nDZ5MTBh/3ya9f8J/FDQrm2Fld39tGCcKt1EYgOOobGB+Yr5rFL3oA+tPtNtNPHdaZdRXcbLvVoJ1bj3xzj3pb3UbwNu893Xr5b4ZTXyRp/8Ax+3X/XI19GeAf+PWL/r3SgDe1CT7ZFE9wtum05CNCBn6EVzOvXUcgBEUIcHsTGR+Oa6W5/g/3qwdX+4/0NAGKb8llBiDqvpJn8z3q3Z+INQtpxLa7oFK7WUsuHHdWBGGHsa5u+/48G+tQ2P/AB7/AI0AnbVHotlfq9ncvpOlRWV5c7Vnkhc7WQHOFQ/dydpODj5RgCtLSf7fW3cYtpYSc7TjP41h+F/9av4V2Np/rTUxioq0VY0q1qlaXNUk2/M5PV9amieQ3emyRsOFwTt/AYrgNd1Ke5MkKrdbW5ARSp/OvTPFv+tSuTuvuN9DVGZ5RqFtcqxkYSecTwuzJA9+KrTwySsm4ueMtkYxXpNh91vpXEeIP+Pu5+tAGI7vAGVJCu7+EColmkXhXZfpUXY0v8VAD5ZXlbLsW+pplFHc0AFKaT+IUrdaADp0pKQ9ad60AIOtFBoHWgBaTtQelA6mgC/ptrZXFrfSXuprZTQput4jbvL9pb+6CvCduW9aoZ6evpS+tHegBKKP4qKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrows point to a retromembranous bleed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28293=[""].join("\n");
var outline_f27_40_28293=null;
var title_f27_40_28294="Complete transverse vag septum";
var content_f27_40_28294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56204%7EOBGYN%2F80278%7EOBGYN%2F54407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56204%7EOBGYN%2F80278%7EOBGYN%2F54407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse vaginal septum with microperforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Agenesis (atresia) of the lower vagina, or thick transverse vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28294=[""].join("\n");
var outline_f27_40_28294=null;
var title_f27_40_28295="Continuous renal replacement therapy in acute kidney injury (acute renal failure)";
var content_f27_40_28295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28295/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/40/28295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis may be required in patients with severe acute kidney injury (acute renal failure). Most patients have been treated with hemodialysis, with the dialysis prescription varying in part with the presence or absence of hypercatabolism. An alternative approach is the use of continuous renal replacement therapy (CRRT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSSIBLE DIFFERENCES BETWEEN INTERMITTENT HEMODIALYSIS AND CRRT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily or every other day conventional hemodialysis is the standard dialytic regimen for the hemodynamically stable patient with severe acute renal failure. However, hypotension, due in part to",
"    <strong>",
"     rapid",
"    </strong>",
"    fluid and solute removal, is one of the most common complications with this technique, making it less desirable in the patient who is hypotensive or hemodynamically unstable. In contrast, the rate of fluid and solute removal is",
"    <strong>",
"     slow",
"    </strong>",
"    and hypotension is less common with the CRRTs, such as continuous arteriovenous hemofiltration or hemodialysis (CAVH or CAVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. A review of the characteristics of the different types of CRRT is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRRT has the additional advantage of effectively removing excess fluid in hypotensive patients, while hemodialysis is frequently limited by a further reduction in blood pressure in this setting.",
"   </p>",
"   <p>",
"    The relative hemodynamic instability associated with hemodialysis is related to several factors, which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapid rate of solute removal results in an abrupt fall in plasma osmolality that induces further extracellular volume depletion by promoting osmotic water movement into the cells (",
"      <a class=\"graphic graphic_figure graphicRef53752 \" href=\"UTD.htm?3/31/3582\">",
"       figure 1",
"      </a>",
"      ). The reduction in plasma osmolality itself may contribute to the development of hypotension.",
"     </li>",
"     <li>",
"      Hemodialysis may impair the protective sympathetic response to volume depletion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It must be emphasized, however, that the protection afforded by CRRT is",
"    <strong>",
"     relative",
"    </strong>",
"    , not absolute. Hypotension can still occur if too much fluid is removed or if fluid is removed too quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Solute removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to being better tolerated hemodynamically, CRRT is also as efficient in removing solutes over the course of 24 to 48 hours as conventional hemodialysis. Although the clearance rate of small solutes (such as urea) is slower per unit time with CRRT (17",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with CAVHD versus more than 160",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with hemodialysis), the rates are closer at 24 hours and more urea is removed over 48 hours with CRRT than with a single run of hemodialysis (",
"    <a class=\"graphic graphic_table graphicRef65154 \" href=\"UTD.htm?3/26/3501\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Removal of immunomodulatory substances in sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The less porous membranes used with conventional hemodialysis are less efficient in removing middle to large molecules with cardiodepressant, vasodilatory, or immunomodulatory properties in septic or highly catabolic patients. Examples of such toxins are endotoxin, interleukin-1, complement anaphylatoxins, platelet activating factor, and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental and some clinical evidence suggests that large volume hemofiltration more effectively removes some of these substances, possibly leading to better preservation of cardiovascular function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. One report, for example, evaluated 16 patients with sepsis, multiple organ dysfunction, and acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/9\">",
"     9",
"    </a>",
"    ]. Hemofiltration did not induce significant mediator activation and did not lead to cytokine removal. There was, however, increased removal of complement anaphylatoxins. Furthermore, the ultrafiltrate from these patients significantly stimulated peripheral blood mononuclear cells in vitro and enhanced tumor necrosis factor release; on the other hand, it reduced lymphocyte production of IL-2 and IL-6. These effects were not seen with ultrafiltrate from normal volunteers.",
"   </p>",
"   <p>",
"    The ability of hemofiltration to remove immunomodulatory substances may lead to an improvement in patient outcome among those with sepsis and acute kidney injury. Although not yet studied in large randomized prospective controlled studies, there is some evidence that hemofiltration may provide some benefit in those with sepsis and acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot prospective study, 20 patients with septic shock and acute renal failure were randomly assigned to either high (65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) or low volume (35",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) hemofiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/17\">",
"       17",
"      </a>",
"      ]. High volume hemofiltration was associated with decreased mean norepinephrine dose and increased urine output. Survival at 28 days was the same in both groups.",
"     </li>",
"     <li>",
"      One retrospective study evaluated the effects of isovolemic hemofiltration on physiological and clinical outcomes in 80 patients with septic shock and oliguric acute kidney injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/12\">",
"       12",
"      </a>",
"      ]. Prior to 1999, 40 patients had received conventional supportive therapy; subsequently, 40 patients received hemofiltration at 45",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour over the first six hours, which was followed by conventional CVVH. Incorporation of isovolemic hemofiltration into the treatment regimen significantly improved oxygenation and mean arterial pressure. Survival at 28 days was also significantly better (55 versus 28 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study in larger better designed studies is required to understand the role of this modality in acute renal failure and sepsis. Furthermore, the early initiation of this intervention (isovolemic hemofiltration) may be very important. However, a randomized prospective study found that early intervention with low volume hemofiltration (25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) was deleterious in those with severe sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The IVOIRE study is specifically designed to address many of these issues regarding high volume hemofiltration in patients with septic shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;No modality of renal replacement therapy in the critically ill patient with acute renal failure, including intermittent hemodialysis, peritoneal dialysis, and the many forms of CRRT, has been clearly shown to have a survival benefit. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE OF CONTINUOUS RENAL REPLACEMENT THERAPY AND CHOICE OF DIALYSIS MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of dialytic technique is dependent upon a variety of factors including availability, the expertise of the clinician, hemodynamic stability, and the degree to which solutes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid must be removed. In addition, comorbid conditions may affect the decision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal drains",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      new incisions generally preclude peritoneal dialysis.",
"     </li>",
"     <li>",
"      Severe peripheral vascular disease or coagulopathy are general contraindications to cannulation of a major artery. Patients at high risk for bleeding during CAVH can be treated with minimal dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or regional citrate anticoagulation (if there is a diffusion component) to prevent clotting in the dialyzer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"       \"Hemodialysis anticoagulation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of continuous modality or intermittent HD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hemodialysis is the standard modality in hemodynamically stable patients with acute renal failure, CRRT is used in selected cases. The determining factors of which modality is chosen include the catabolic state, hemodynamic stability, and whether the primary goal is solute removal (eg, uremia, hyperkalemia), fluid removal, or both. (",
"    <a class=\"graphic graphic_table graphicRef80028 \" href=\"UTD.htm?36/44/37579\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CRRTs in patients with acute kidney injury are most often selected when hemodynamic instability precludes the use of standard three to four hour intermittent dialysis. While randomized controlled trials have failed to prove better outcomes with CRRTs when compared to intermittent dialysis, many clinicians prefer them because of their ease of use and the security perceived by slow therapy. Since there is no proven benefit of CRRT versus intermittent dialysis in this setting, the renal replacement modality selection is based on ease of operation and perceived benefit.",
"   </p>",
"   <p>",
"    Solute removal occurs primarily by diffusion from the plasma into the dialysate during dialysis and, to a much lesser degree, by convection during ultrafiltration as solvent drag carries small and intermediate sized solutes with the water. Smaller solutes (such as urea and electrolytes) are removed in roughly the same concentration as the plasma with hemofiltration; as a result, the rate of solute clearance is equal to the ultrafiltration rate unless there is concurrent diffusive loss. There is also no change in the plasma concentrations of small solutes with hemofiltration alone, unless they are lowered by dilution by the administration of replacement fluid to prevent extracellular volume depletion.",
"   </p>",
"   <p>",
"    The rate of solute diffusion is determined by a number of factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The surface area and unit",
"      <strong>",
"       solute",
"      </strong>",
"      permeability of the dialysis membrane.",
"     </li>",
"     <li>",
"      The blood and dialysate flow rates which, if increased, maintain a maximum concentration gradient between these two compartments.",
"     </li>",
"     <li>",
"      The duration of dialysis (only if a favorable concentration gradient persists for continued diffusion).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison, the rate of solute removal by ultrafiltration is influenced by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The transmembrane pressure gradient that provides the driving force for ultrafiltration.",
"     </li>",
"     <li>",
"      The surface area and unit",
"      <strong>",
"       water",
"      </strong>",
"      permeability of the dialysis membrane.",
"     </li>",
"     <li>",
"      The duration of hemofiltration.",
"     </li>",
"     <li>",
"      The blood flow rate, which acts indirectly by moving nonfiltered plasma proteins away from the inner wall of the dialysis membrane; preventing local protein accumulation maintains water permeability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These determinants apply to",
"    <span class=\"nowrap\">",
"     hemodialysis/hemofiltration,",
"    </span>",
"    but not to peritoneal dialysis.",
"   </p>",
"   <p>",
"    Hypotension, either at baseline or during the procedure, may be a limiting feature with conventional hemodialysis but should not occur with slow fluid and solute removal in peritoneal dialysis. However, the latter is often not an option in acutely ill patients.",
"   </p>",
"   <p>",
"    Slow fluid and solute removal can also be achieved with CRRT. In addition to being better tolerated hemodynamically, CRRT is also as efficient in removing solutes over the course of 24 to 48 hours as conventional hemodialysis. Although the clearance rate of small solutes (such as urea) is slower per unit time with CRRT (17",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with CAVHD versus more than 160",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with hemodialysis), the rates are closer at 24 hours and more urea is removed over 48 hours with CRRT than with a single run of hemodialysis.",
"   </p>",
"   <p>",
"    Numerous centers have begun utilizing dialysis machines to deliver a dialysate flow of only 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for periods ranging from 8 to 24 hours per day. Advantages with this technique include a high hemodynamic tolerance and an unsurpassed solute removal capability. This dialytic intervention is named sustained or slow low efficiency dialysis (SLED, or extended daily dialysis (EDD)). \"Hybrid hemodialysis\" is probably a better and more inclusive descriptive term for these therapies.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     SLED/EDD",
"    </span>",
"    hybrid technique offers every advantage of CRRT, but does not require any new equipment acquisition since some hemodialysis machines can also be used for regular hemodialysis treatments. Thus,",
"    <span class=\"nowrap\">",
"     SLED/EDD",
"    </span>",
"    hybrids are well suited for centers in which there is limited support for CRRT. The therapy can be applied to all patients in ARF requiring dialytic support who manifest intolerance to regular hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .) Probably the most common usage of these hybrid techniques has been as a bridge between CRRT and intermittent (regular) hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Slow continuous ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow continuous ultrafiltration (SCUF) is designed to remove up to",
"    <strong>",
"     6 to 7 L",
"    </strong>",
"    of fluid per day without requiring replacement fluid other than for hyperalimentation. Solute removal is",
"    <strong>",
"     minimal",
"    </strong>",
"    with this technique, being limited by the low ultrafiltration rate and lack of dialysis. As an example, the clearance of urea and other small solutes is equal to the ultrafiltration rate of approximately 4 to 5",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Thus, SCUF is not useful in patients who are uremic or hyperkalemic.",
"   </p>",
"   <p>",
"    Either arteriovenous or venovenous access can be used for SCUF. Arteriovenous access, without an extracorporeal pump, is generally sufficient to achieve the desired rate of fluid loss. The low ultrafiltration rate (UFR) of about 5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    does not require a high rate of blood flow (Qb) through the filter. The Qb can be estimated by flushing the extracorporeal circuit with saline and then measuring the time for blood to refill the circuit. The volume of the lines and filter are noted in the manufacture's package literature.",
"   </p>",
"   <p>",
"    Practical goals are a UFR of 5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a Qb of 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    If the hematocrit is between 35 and 40 percent, then this Qb represents a plasma flow of approximately 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with a filtration fraction of 10 percent. If necessary, the UFR can be increased by raising Qb or by adding suction to the filtrate drainage system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/20\">",
"     20",
"    </a>",
"    ]. The Qb can be raised by increasing the systemic blood pressure or by inserting an extracorporeal blood pump into the circuit. Short catheters with wide internal diameters that have been specifically designed for CAVH should be used for arterial access, since they maximize Qb [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, however, the UFR is too rapid. In this setting, ultrafiltration can be slowed by raising the level of the bag into which the ultrafiltrate drains. Most SCUF is now performed with venovenous access, and UFR is completely controlled by the operating parameters of the automated equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Continuous arteriovenous hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAVH is similar to SCUF except that ultrafiltration is allowed at a greater degree than required for the restoration of euvolemia to increase solute removal. As a result, replacement fluid is necessary to prevent volume depletion. However, the rate of solute clearance with CAVH is still relatively low even at a high UFR (",
"    <a class=\"graphic graphic_table graphicRef65154 \" href=\"UTD.htm?3/26/3501\">",
"     table 1",
"    </a>",
"    ). One method to increase the removal of urea (and probably other small, lipid-soluble solutes) is to administer the replacement fluid before the filter; this",
"    <strong>",
"     predilution",
"    </strong>",
"    lowers the plasma urea concentration, thereby allowing urea to diffuse from within red cells into the plasma water. The increased total extracellular urea entering the filter enhances the urea clearance rate by approximately 15 percent, especially if 200 mmHg of suction is also used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with any hemofiltration procedure, the aim is to keep the filtration fraction at 10 to 20 percent. At 40 percent and above, sludging occurs in the filter, compromising further fluid removal. The technical aspects of SCUF and CAVH are discussed in depth elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Continuous venovenous hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous venovenous hemofiltration (CVVH) is similar to CAVH, except that an extracorporeal blood pump is required that allows the physician to control the flow rates within the system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/25\">",
"     25",
"    </a>",
"    ]. The blood pump assures a fast and stable Qb that can be set, for example, at approximately 250",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    If the hematocrit is 33 percent, then the plasma flow rate will be 167",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    A filtration fraction of 10 percent in this setting results in a UFR of 16.7",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    which is equal to 1",
"    <span class=\"nowrap\">",
"     L/h",
"    </span>",
"    or 24",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (four times greater than that with SCUF). Most of this fluid will need to be replaced; if given before the filter (predilution), the urea clearance will again be enhanced by approximately 15 percent. Water exchanges of 40 to 60",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    are usually sufficient, but catabolic patients with an increased urea load may require more than 60",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more predictable blood flow rate and the associated ability to achieve a high ultrafiltration rate make CVVH preferable to CAVH when solute removal is important, as in hypercatabolic patients with a high BUN (",
"    <a class=\"graphic graphic_table graphicRef65154 \" href=\"UTD.htm?3/26/3501\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous arteriovenous hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous arteriovenous hemodialysis (CAVHD) differs from CAVH in that dialysis fluid flows through the filter in a compartment separated from the blood by the dialysis membrane. The efficiency of CAVHD is, as with CAVH, dependent upon Qb. However, the UFR is not as high as that achievable with CAVH alone. Thus, fluid removal with CAVHD is slower, but a greater rate of solute clearance can be achieved (",
"    <a class=\"graphic graphic_table graphicRef65154 \" href=\"UTD.htm?3/26/3501\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clearance rates with CAVHD are dependent upon both blood and dialysate flow rates, which determine the concentration gradient between these two compartments. At Qb values above 80",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the dialysate fluid tends to become saturated with small solutes (ie, the concentration in the dialysate approaches that in the plasma, preventing further diffusive loss). In this setting, the main way to increase clearance is to raise the dialysate flow rate (Qd) from 1 up to 2",
"    <span class=\"nowrap\">",
"     L/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Once the Qd reaches 2",
"    <span class=\"nowrap\">",
"     L/h,",
"    </span>",
"    additional attempts to enhance clearance should be directed at increasing Qb, either by using a blood pump or turning up the pump rate if it is already in use.",
"   </p>",
"   <p>",
"    A final way to raise solute clearance above that achieved by diffusion is to increase convective clearance. This can be achieved by enhancing ultrafiltration beyond the amount necessary to reestablish euvolemia, with replacement fluid then being given to prevent volume depletion. Thus, the highest solute clearances are achieved in CAVHD with a high Qb, high Qd, high UFR, and high rate of fluid replacement. For all the therapies discussed the highest clearances are in the extracorporeal pumped venovenous therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Continuous venovenous hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous venovenous hemodialysis (CVVHD) combines the processes of diffusive and convective clearances; as with CVVH, it utilizes a blood pump to maximize the delivery of blood to the extracorporeal device. The transmembrane pressure generated by the blood pump assures net ultrafiltration unless the dialysate outflow is regulated to ensure that ultrafiltration is retarded. Under routine operating conditions, the blood flow (Qb) varies from 150 to 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and the dialysate flow (Qd) from 1 to 2",
"    <span class=\"nowrap\">",
"     L/hour.",
"    </span>",
"   </p>",
"   <p>",
"    The equipment required to provide CVVHD can be simple or complex. As an example, components, such as a blood pump, may be combined with separate infusion pumps; by comparison, specialized equipment made by many vendors can be utilized alone to deliver fresh dialysate to the filter and to govern the rate of dialysate exiting the filter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some machines also can be utilized for CVVHD. This system uses a proportioning system to generate bicarbonate dialysate from concentrate. The Qd can be adjusted to as high as 6",
"    <span class=\"nowrap\">",
"     L/h,",
"    </span>",
"    thereby providing an enormous clearance potential with continuous therapy. This approach can be applied for as little as eight hours per day (or nocturnally) because the solute clearance is high and the ultrafiltration needs can frequently be realized in this short period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28295/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This hybrid dialytic intervention, named sustained or slow low efficiency dialysis (SLED), or extended daily dialysis (EDD), may soon become the \"gold standard\" for renal replacement therapy during acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of peritoneal dialysis in acute renal failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=see_link\">",
"     \"Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal replacement therapy may be required in patients with severe acute kidney injury (acute renal failure). Although most patients are treated with hemodialysis, an alternative approach is the use of continuous renal replacement therapy (CRRT). A number of possible differences between intermittent hemodialysis and CRRT include hemodynamic stability, solute removal, removal of substances in those with sepsis, and effects on mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Possible differences between intermittent hemodialysis and CRRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of dialytic technique is dependent upon a variety of factors including availability, the expertise of the clinician, hemodynamic stability, comorbid conditions, and the degree to which solutes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid must be removed. CRRTs are generally most often selected in those with acute kidney injury when hemodynamic instability precludes the use of intermittent dialysis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Choice of continuous modality or intermittent HD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different continuous modalities include slow continuous ultrafiltration, continuous arteriovenous hemofiltration, continuous venovenous hemofiltration, continuous arteriovenous hemodialysis, continuous venovenous hemodialysis, and peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use of continuous renal replacement therapy and choice of dialysis modality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/1\">",
"      Golper TA. Indications, technical considerations, and strategies for renal replacement therapy in the intensive care unit. J Intensive Care Med 1992; 7:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/2\">",
"      Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 1997; 336:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/3\">",
"      Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993; 40:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/4\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/5\">",
"      Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/6\">",
"      Moldawer LL. Interleukin-1, TNF alpha and their naturally occurring antagonists in sepsis. Blood Purif 1993; 11:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/7\">",
"      Stein B, Pfenninger E, Gr&uuml;nert A, et al. Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 1990; 16:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/8\">",
"      Gomez A, Wang R, Unruh H, et al. hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 1990; 73:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/9\">",
"      Hoffmann JN, Hartl WH, Deppisch R, et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/10\">",
"      Barzilay E, Kessler D, Berlot G, et al. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989; 17:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/11\">",
"      Storck M, Hartl WH, Zimmerer E, Inthorn D. Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure. Lancet 1991; 337:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/12\">",
"      Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006; 32:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/13\">",
"      Cole L, Bellomo R, Journois D, et al. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 27:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/14\">",
"      Kvist T, Reit C. Results of endodontic retreatment: a randomized clinical study comparing surgical and nonsurgical procedures. J Endod 1999; 25:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/15\">",
"      Cole L, Bellomo R, Silvester W, Reeves JH. A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a \"closed\" ICU system. Am J Respir Crit Care Med 2000; 162:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/16\">",
"      Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/17\">",
"      Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008; 34:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/18\">",
"      Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/19\">",
"      Wu VC, Wang CH, Wang WJ, et al. Sustained low-efficiency dialysis versus continuous veno-venous hemofiltration for postsurgical acute renal failure. Am J Surg 2010; 199:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/20\">",
"      Kaplan AA, Longnecker RE, Folkert VW. Suction-assisted continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 1983; 29:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/21\">",
"      Olbricht CJ, Haubitz M, H&auml;bel U, et al. Continuous arteriovenous hemofiltration: in vivo functional characteristics and its dependence on vascular access and filter design. Nephron 1990; 55:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/22\">",
"      Kaplan AA. Predilution versus postdilution for continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 1985; 31:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/23\">",
"      Kaplan AA. Clinical trials with predilution and vacuum suction: enhancing the efficiency of the CAVH treatment. ASAIO Trans 1986; 32:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/24\">",
"      Golper TA. Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 1985; 6:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/25\">",
"      Macias WL, Mueller BA, Scarim SK, et al. Continuous venovenous hemofiltration: an alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure. Am J Kidney Dis 1991; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/26\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/27\">",
"      Sigler MH, Teehan BP. Solute transport in continuous hemodialysis: a new treatment for acute renal failure. Kidney Int 1987; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/28\">",
"      van Geelen JA, Vincent HH, Schalekamp MA. Continuous arteriovenous haemofiltration and haemodiafiltration in acute renal failure. Nephrol Dial Transplant 1988; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/29\">",
"      Hu, KT, Yeun, JY, Craig, M, et al. Extended daily dialysis: An alternative to continuous venovenous hemofiltration in the intensive care unit. Blood Purif 1999; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28295/abstract/30\">",
"      Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60:777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1845 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28295=[""].join("\n");
var outline_f27_40_28295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSSIBLE DIFFERENCES BETWEEN INTERMITTENT HEMODIALYSIS AND CRRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Solute removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Removal of immunomodulatory substances in sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect on mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE OF CONTINUOUS RENAL REPLACEMENT THERAPY AND CHOICE OF DIALYSIS MODALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of continuous modality or intermittent HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Slow continuous ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Continuous arteriovenous hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Continuous venovenous hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous arteriovenous hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Continuous venovenous hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1845|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/31/3582\" title=\"figure 1\">",
"      Water shifts in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1845|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/26/3501\" title=\"table 1\">",
"      Solute clearance in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/44/37579\" title=\"table 2\">",
"      Choice of dialysis in ARF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20935?source=related_link\">",
"      Continuous venovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=related_link\">",
"      Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_40_28296="Physical exam skin front";
var content_f27_40_28296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Common disorders encountered during the physical examination of skin, front view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 675px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Fitzpatrick, TB, Bernhard, JD, Copley, TG. In: Dermatology in General Medicine, Freedberg, IN, Eisin, AZ, Wolff, K, et al. (Eds), 5th ed, McGraw-Hill 1999. Copyright &copy; 1999 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28296=[""].join("\n");
var outline_f27_40_28296=null;
var title_f27_40_28297="Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)";
var content_f27_40_28297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Richard C Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28297/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/40/28297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolysis, defined as the dissolution of thrombus or, more specifically, the breakdown of fibrin (fibrinolysis), is a critical component of vascular homeostasis. If not for an intact fibrinolytic system, even the smallest thrombus required to stem blood loss following minor vessel wall injury would progress rapidly and potentially compromise tissue perfusing blood flow. Furthermore, intravascular fibrinolysis represents a vital teleologic defense mechanism, preventing \"hemostasis in the wrong place\" that could, under pathologic conditions, occur in the coronary arterial bed and cerebral vasculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link\">",
"     \"Fibrinolytic markers and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An understanding of fibrinolysis has paved the way for the development of fibrinolytic (thrombolytic) agents that can be used therapeutically for a variety of thrombotic disorders including myocardial infarction, ischemic stroke, and acute pulmonary embolism. At the present time, fibrinolytic agents are used most often in the early treatment of acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fundamental biology and physiology of the vascular endothelium and the mechanisms of thrombosis are reviewed here. This will be followed by a discussion of the mechanisms of and the factors influencing thrombolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VASCULAR ENDOTHELIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular endothelium is intricately related to normal vessel responsiveness, and thromboresistance. It is a multifunctional organ system composed of metabolically active and physiologically responsive component cells that meticulously regulate blood flow, according to metabolic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anatomic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial cells form a single layer of simple squamous lining cells. The cells themselves are polygonal in shape, varying between 10 and 50 &micro;m in diameter, and elongated in the long axis, orienting the cellular longitudinal dimension in the direction of blood flow. The endothelial cell has three surfaces:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonthrombogenic (luminal)",
"     </li>",
"     <li>",
"      Adhesive (subluminal)",
"     </li>",
"     <li>",
"      Cohesive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The luminal surface is smooth and devoid of electron-dense connective tissue. The luminal membrane or glycocalyx adds significantly to the vessel's thromboresistant properties, carrying a negative charge that repels similarly charged circulating blood cells.",
"   </p>",
"   <p>",
"    The subluminal (abluminal) surface adheres to connective tissue within the subendothelial zone. Small processes penetrate through a series of internal layers to form myoendothelial junctions with subjacent smooth muscle cells.",
"   </p>",
"   <p>",
"    The cohesive surface of the vascular endothelium joins adjacent cells to one another by cell junctions of two basic types: occluding (tight) and communicating (gap).",
"   </p>",
"   <p>",
"    There is also a cell-matrix interface (adherens junctions), which is modulated, at least in part, by endothelial cell-cell tugging forces. The up-regulation and down-regulation of tugging force correlates with myosin activation and inhibition, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thromboresistant properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an active site of protein synthesis, endothelial cells synthesize, secrete, modify, and regulate connective tissue components, vasodilators, vasoconstrictors, anticoagulants, procoagulants, fibrinolytic proteins, and prostanoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/2\">",
"     2",
"    </a>",
"    ]. One of the most important functions of the vascular endothelium is to prevent the initiation and development of nonphysiologic thrombi (ie, thrombosis not required for hemostatic regulation). This effect is influenced by a variety of factors:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prostacyclin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostacyclin (PGI2) is a potent vasodilator that is released locally in response to biochemical and mechanical mediators. It also inhibits platelet aggregation by increasing intracellular cyclic adenosine monophosphate (cAMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/3\">",
"     3",
"    </a>",
"    ]. The vasodilatory and platelet inhibiting properties of prostacyclin directly oppose the effects of thromboxane and are mediated by interactions at their respective receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide is an L-arginine derivative that relaxes smooth muscles by increasing intracellular cyclic guanosine monophosphate (cGMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It is released locally in response to a number of biochemical mediators, including thrombin, bradykinin, thromboxane A2, histamine, adenine nucleotides, shear stress, and aggregating platelets. In addition to its vasoactive properties, nitric oxide is also a potent inhibitor of platelet adhesion and aggregation; the antiaggregatory effect may be synergistic with that of prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/7\">",
"     7",
"    </a>",
"    ]. Enhanced production of nitric oxide also reduces endotoxin- and cytokine-induced expression of tissue factor and the prothrombotic potential of the endothelial cell [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with atherosclerosis uniformly have endothelial dysfunction with reduced nitric oxide secretion in response to acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/9\">",
"     9",
"    </a>",
"    ]. Emerging data suggest that acetylcholine may render nitric oxide synthase dysfunctional among patients with advanced coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/10\">",
"     10",
"    </a>",
"    ]. This may contribute to the increased platelet aggregability and thrombotic events seen in atherosclerosis. L-arginine, by increasing nitric oxide activity, inhibits platelet aggregation. Support for the clinical importance of this effect comes from a study of 42 patients undergoing carotid endarterectomy who were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ; compared to placebo, treatment with L-arginine or S-nitrosoglutathione, a physiologic nitric oxide donor, reduced the extent of cerebral platelet embolization, as determined by Doppler signals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Plasminogen activators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial cells synthesize and release activators, which are capable of converting plasminogen to the serine protease plasmin, an enzyme that proteolytically degrades fibrin (and fibrinogen). Tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (UK) generate plasmin locally; as a result, fibrinolysis is limited to the immediate environment. Stimuli for the release of vascular plasminogen activators include epinephrine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , thrombin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , interleukin-1, venous occlusion, aggregating platelets, and dDAVP, a nonpressor analogue of antidiuretic hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Plasminogen activator inhibitor-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen activator inhibitor (PAI)-1 is a globular glycoprotein with a molecular weight of 50,000 daltons; it is comprised of 379 amino acids in a single chain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/13\">",
"     13",
"    </a>",
"    ]. The primary structure of PAI-1 designates it as a member of the superfamily of serine protease inhibitors (serpins); PAI-1 is structurally similar to other serpins, including angiotensinogen, antithrombin-III, and alpha-2 antiplasmin. In its latent form, PAI-1 is not susceptible to cleavage by tPA nor does it form complexes with tPA; however, in its active form, it is both susceptible to cleavage and readily forms complexes with tPA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Heparin-like molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, mast cells were thought to be the only cells capable of synthesizing anticoagulant-active",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ; however, endothelial cells are also capable of synthesizing heparin-like molecules with anticoagulant properties [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/15\">",
"     15",
"    </a>",
"    ]. As a result, vascular thromboresistance is mediated, at least in part, through the interaction of heparin-like substances with antithrombin and heparin cofactor II, both of which are located on the endothelial surface, thereby accelerating the neutralization of hemostatic (procoagulant) proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Heparin cofactor II",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    cofactor II, a potent inhibitor of thrombin, is secreted by the liver into circulating blood where it is present at a concentration of approximately 1.2",
"    <span class=\"nowrap\">",
"     &micro;mol/L.",
"    </span>",
"    At least four distinct subspecies have been identified in endothelial cells: two high molecular weight complexes, a heterodimeric form bound to fibronectin and two small molecules referred to as decorin and biglycan. The thrombin inhibitory activity of heparin cofactor II is stimulated physiologically by dermatan sulfate (a heparinoid) and, under high shear stress, heparan sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antithrombin III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin III is a plasma glycoprotein that circulates at a concentration of approximately 2.3",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    It is capable of neutralizing most coagulation proteins, including thrombin and factors VIIa, IXa, Xa, XIa, and XIIa by covalent binding at their active sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Protein C and protein S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C and protein S have anticoagulant activity. Protein C is synthesized in the liver and is secreted into plasma as a two-chain disulfide bonded glycoprotein. It acts as an important anticoagulant (activated protein C) (APC) by preferentially deactivating the activated forms of factor V and factor VIII (principally by cleaving their heavy chains). Protein S supports the anticoagulant function of activated protein C by promoting its interaction with factors Va and VIIIa. Because protein S enhances activated protein C-mediated factor Va activation by only twofold, it may also exert an APC-independent anticoagulant effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tissue factor pathway inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue factor pathway inhibitor (TFPI)-1 is also located on the endothelial surface, where it acts against the combined action of tissue factor and factor VIIa in the presence of factor Xa. The proposed mechanism for inhibition of tissue factor-factor VIIa involves the formation of a quaternary complex with TFPI and factor X in a two-step reaction: factor Xa generated by tissue factor-factor VIIa binds reversibly with TFPI; this binary complex binds, in a calcium-dependent manner, to membrane bound tissue factor-factor VIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Annexin V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annexins are a family of nonglycosylated proteins that bind to negatively charged phospholipids, including phosphatidylserine and phosphatidylethanolamine. One of the thirteen identified annexins, annexin V, is a potent endothelial surface anticoagulant based upon its ability to displace phospholipid-dependent coagulation factors; it also attenuates platelet adhesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiinflammatory properties of the normal vessel wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiinflammatory properties that characterize the normal vessel wall involve a variety of external signals and intracellular mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The external signals include antiinflammatory cytokines, high density lipoprotein (HDL) cholesterol, and several angiogenic growth factors. Laminar shear stress, through the production of nitric oxide (NO), is of particular importance in protecting endothelial cells against inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following factors exert antiinflammatory activity through a variety of mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transforming growth factor-beta 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interleukin (IL)-10 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/23-27\">",
"       23-27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IL-4 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HDL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/28-32\">",
"       28-32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Physiologic shear stress [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second line of defense is achieved by vascular endothelial cells and smooth muscle cells, which regulate chemokine-induced immunoinflammatory responses. Surface glycosaminoglycans (GAGs) contribute to this protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In addition, several antiapoptotic genes (cytoprotective genes) possess important antiinflammatory properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endothelial cell function and coronary atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial cell dysfunction, even in its early stages impairs an ability to regulate inflammation and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The most common disorder associated with impaired vascular thromboresistance is atherosclerosis (",
"    <a class=\"graphic graphic_table graphicRef63061 \" href=\"UTD.htm?32/8/32907\">",
"     table 1",
"    </a>",
"    ). Damaged or \"perturbed\" endothelial cells, however, can lose their ability to maintain thromboresistance and can actually promote thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Direct evidence for endothelial injury and the loss of endothelial cells from the intima is provided by the demonstration of circulating endothelial cells in patients with unstable angina or acute myocardial infarction, but not in those with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=see_link\">",
"     \"The coronary microcirculation in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assembly of the prothrombinase complex, stimulating the thrombin generation, can take place on the endothelial surface of atherosclerotic vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Furthermore, impaired local fibrinolytic activity can prevent clot dissolution. The promotion of thrombosis by endothelial dysfunction is in part mediated by an abnormal response to thrombin generation and activity. Under normal circumstances thrombin stimulates platelet-mediated vasoconstriction (caused by thromboxane A2 release), which is prevented by the simultaneous thrombin-induced release of prostacyclin and nitric oxide from endothelial cells. In atherosclerotic vessels, however, the response to thrombin is almost entirely vasoconstrictive (and thrombotic) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THROMBOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal physiologic conditions, blood components interact with the intact vascular endothelium primarily for the purpose of day-to-day vascular repair. The exposure of circulating blood to disrupted or dysfunctional surfaces (as with rupture of an atherosclerotic plaque) initiates a series of complex, yet orderly, steps that give rise to the rapid deposition of platelets, erythrocytes, and insoluble fibrin, producing a mechanical barrier to blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most instances, thrombus occurring in the arterial system is comprised of platelets and fibrin in a tightly packed network. In contrast, venous thrombi consist of a more loosely network of erythrocytes, leukocytes, and fibrin.",
"   </p>",
"   <p>",
"    The process of vascular thrombosis, particularly in the arterial system, is dynamic, with clot formation and dissolution occurring almost simultaneously. The overall extent of thrombosis and ensuing circulatory compromise is therefore determined by the relation between these opposing forces. If local stimuli exceed the vessel's thromboresistant capabilities, thrombosis will occur. If, on the other hand, the stimulus toward thrombosis is not strong and intrinsic defenses are intact, clot formation of clinical importance is unlikely. In some circumstances, systemic factors contribute to or magnify local prothrombotic factors, \"shifting\" the balance toward thrombosis.",
"   </p>",
"   <p>",
"    Overall, the site, size, and composition of thrombi forming within the arterial and venous circulatory systems are determined by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alterations in blood flow and shear stress",
"     </li>",
"     <li>",
"      Thrombogenicity of vascular surfaces",
"     </li>",
"     <li>",
"      Concentration and reactivity of plasma cellular components",
"     </li>",
"     <li>",
"      Effectiveness of intrinsic protective mechanisms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The critical steps in arterial thrombosis, as occurs in acute myocardial infarction are platelet deposition, activation of coagulation factors, and fibrin formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Platelet deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets attaching to nonendothelialized or disrupted endothelial surfaces undergo rolling, tethering, adherence activation and aggregation along the involved area, followed by subsequent recruitment to form a rapidly enlarging platelet mass. Under physiologic conditions this represents the primary step in hemostasis. In pathologic thrombosis, however, platelet adherence initiates a process ultimately leading to circulatory compromise. Although activated platelets are most frequently observed in patients with acute coronary syndromes, they have also been reported in those with clinically stable coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of platelet deposition involves the following steps (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Normal platelet function'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activated endothelium enhances the expression of the vitronectin (integrin a(v) b(3)) receptor on the luminal surface, prompting the adhesion of platelets via a fibrinogen bridge between this endothelial receptor and the glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor found on activated platelet [",
"      <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Platelet attachment to collagen or exposed surface adhesive proteins",
"     </li>",
"     <li>",
"      Platelet activation and intracellular signaling",
"     </li>",
"     <li>",
"      Expression of platelet receptors for adhesive proteins",
"     </li>",
"     <li>",
"      Platelet aggregation",
"     </li>",
"     <li>",
"      Platelet recruitment mediated by thrombin, collagen, thromboxane A2, and adenosine diphosphate (ADP) forming a template for coagulation protein assembly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Activation of coagulation factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin is rapidly generated in response to vascular injury. It also plays a pivotal role in platelet recruitment and the formation of an insoluble fibrin network. The thrombotic process is localized, amplified, and modulated by a series of biochemical reactions driven by the reversible binding of circulating proteins (coagulation factors) to damaged vascular cells, elements of exposed subendothelial connective tissue (especially collagen), platelets (which also express receptor sites for coagulation factors), and macrophages. These events lead to an assembly of enzyme complexes that increase local concentrations of procoagulant substrate; in this way, a relatively minor initiating stimulus can be greatly amplified to yield a thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fibrin formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final phase in thrombus formation involves the generation of a stable fibrin network that provides the structural support for the circulating blood's cellular elements and the scaffolding for vascular remodeling. In this process, thrombin cleaves two small peptides, fibrinopeptide A and fibrinopeptide B, to form fibrin monomers, which in turn polymerize to form soluble fibrin strands. An orderly assembly, branching, and lateral association of fibrillar strands follows, terminating with factor XIII-mediated covalent cross-linking to form a mature fibrin network (mature thrombus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders of fibrinogen\", section on 'Fibrinogen structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrin polymerizes via dynamic, and, in the early phases, noncovalent association of thrombin-exposed knobs with complementary holes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/55\">",
"     55",
"    </a>",
"    ]. It is also possible that fibrin polymerization may occur at low concentrations of fibrinogen and thrombin-spontaneously forming sheets that can transition to fibers by folding and rolling up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     THROMBOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic (fibrinolytic) therapy is used clinically to treat a wide variety of arterial and venous thromboembolic disorders. The most frequent indication is in the treatment of patients with acute myocardial infarction, where it has been shown to limit myocardial necrosis (infarct size), to preserve left ventricular function, and to reduce mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombolytic therapy makes use of the vascular system's intrinsic thromboresistance defense mechanism by accelerating and amplifying the conversion of an inactive precursor, plasminogen, to the active enzyme plasmin. Plasmin hydrolyzes several key bonds in the fibrin (clot) matrix, causing dissolution (lysis) of the clot. As a result coronary arterial blood flow is restored and with it myocardial reperfusion is achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics and properties of both the available and investigational thrombolytic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .) The remainder of this topic review will present the basic principles underlying the clinical use and efficacy of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Plasminogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen is a single-chain glycoprotein consisting of 790 amino acids. Upon exposure to activator species, there is specific cleavage of the single-chain Glu-1-plasminogen at the arginine 560-valine 561 peptide bond to form Glu-1-plasmin, a two-chain serine protease with trypsin-like specificity. The plasminogen molecule also contains specific lysine binding sites, which mediate its interaction with fibrin and alpha-2- plasmin inhibitor. Activation of plasminogen by t-PA is enhanced in the presence of fibrin or at the endothelial cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Plasmin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmin is a serine protease with trypsin-like activity. It attacks lysyl and arginyl bonds of fibrin at two principal sites: the carboxyterminal portion of alpha-chain (polar region) and the coiled-coil connectors containing the alpha, beta, and gamma-chains (",
"    <a class=\"graphic graphic_figure graphicRef77087 \" href=\"UTD.htm?14/25/14749\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70156 \" href=\"UTD.htm?33/3/33851\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Determinants of thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of a thrombolytic agent to dissolve an occlusive coronary artery thrombus is determined by several factors. In basic terms, the agent must be delivered to, bathe, and ultimately infiltrate the thrombus while concomitantly being provided with an adequate amount of substrate (plasminogen) and the appropriate metabolic environment for an enzymatic reaction (conversion of plasminogen to plasmin) to take place. The intrinsic composition or ultrastructure of the thrombus itself also affects its lysability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hemodynamic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the total amount and distribution of coronary blood flow determine oxygen delivery to the myocardium. They may also determine the delivery of enzymatic substrate and plasminogen activators to the occlusive coronary thrombus. Coronary blood flow correlates directly with mean arterial pressure. The flow-pressure curve is relatively flat above 65 to 70 mmHg but declines as mean arterial pressure falls below this level.",
"   </p>",
"   <p>",
"    Experimental data obtained by magnetic resonance imaging and by photographing clot dissolution in vitro have shown that whole blood clots dissolve two orders of magnitude faster when thrombolytic agents are introduced into the clot by pressure-induced permeation than when access is limited solely to diffusion. When a pressure gradient exists along an occlusive clot, plasma flows through pores in the fibrin network and distributes plasminogen activators along the clot. In the absence of a pressure gradient, plasminogen activator molecules diffuse into the clot through the blood clot boundary plane. Over time, the blood clot boundary moves inward as a result of lysis that is spatially restricted to a relatively narrow zone. The velocity of lysis is therefore limited by the diffusion constraints of both the plasminogen activator and plasmin.",
"   </p>",
"   <p>",
"    The importance of perfusion pressure and bulk flow delivery of fibrinolytic agents on the efficacy of thrombolysis can be illustrated by two observations: the rate of dissolution of a coronary artery thrombus is markedly depressed when hypotension is present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]; and the rate of lysis is slow with venous thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, in animal models, the rate of coronary arterial clot dissolution can be restored to normal levels if the blood pressure is raised by aggressive use of vasopressors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/61\">",
"     61",
"    </a>",
"    ] or with intraaortic balloon counterpulsation (",
"    <a class=\"graphic graphic_figure graphicRef59524 \" href=\"UTD.htm?20/2/20525\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/62\">",
"     62",
"    </a>",
"    ]. The impact of raising blood pressure in humans is less well characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Mechanical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An existing arterial stenosis influences blood flow through and beyond the narrowed segment. Experimental studies performed in flow-through models have demonstrated that the hemodynamic severity of a stenosis is determined by the reduction in luminal diameter, the velocity of blood flow, the length of the stenosis, and the viscosity of blood. Coronary artery stenosis diminishes and with increasing severity eventually abolishes the peak reactive hyperemic response after transient complete vessel occlusion, suggesting that dynamic forces are at play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Thrombus composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin assembly is a complex process that is initiated by the proteolytic action of thrombin on fibrinogen. The gelation mechanism consists of two distinct polymerization stages [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Initially the activated fibrin monomers polymerize spontaneously in a linear mode to form staggered chains of protofibril oligomers. The lateral assembly of linear segments allows generation of the three-dimensional network required for gelation.",
"   </p>",
"   <p>",
"    For normal physiologic function, it is essential that the fibrin gel (thrombus) permit transport of both cells and macromolecules yet possess mechanical rigidity. The stiffness of the fibers and the number of contacts between fibers determine the mechanical rigidity of the gel. If many thin fibers with a high-fiber cross-link density are formed, the fibrin network pore size and therefore the mobility of a diffusing species within the gel are decreased.",
"   </p>",
"   <p>",
"    A number of interrelated factors occurring in humans at a site of atheromatous plaque rupture may affect the thrombus composition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/68\">",
"     68",
"    </a>",
"    ]. The weight fraction of a fibrin gel is enhanced by increased fibrinogen concentration. In this setting, the distance between fibers lessens, leading to decreased pore gel size and restricted transport of diffusing species. Increased thrombin concentration, observed commonly in the setting of myocardial infarction, also decreases fiber diameter as does thrombospondin, a large glycoprotein secreted from alpha granules of thrombin-stimulated platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Calcium concentration and pH also have been shown to affect fiber size [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Restricted transport within a fibrin gel, because of a reduction in perfusion pressure or a \"tightly packed\" thrombus, limits the delivery of plasminogen, plasmin, and plasminogen activators, and therefore lysis is compromised. In contrast, increasing fiber size increases porosity and thrombolytic-induced plasmin digestion of fibrin clots [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Plasminogen activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic regulation of plasmin formation in plasma depends primarily upon three factors: plasminogen, the zymogen precursor of plasmin; the presence of plasminogen activators; and the presence of protein inhibitors that inactivate plasmin (",
"    <a class=\"graphic graphic_figure graphicRef77087 \" href=\"UTD.htm?14/25/14749\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The enzymatic conversion of plasminogen to plasmin by urokinase and tissue plasminogen activator is directed by a single-step interaction, whereas streptokinase involves two steps. The generation of plasmin occurs most efficiently at a pH of 7.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/73\">",
"     73",
"    </a>",
"    ]. At a slightly decreased pH (eg, 7.2), the Michaelis constant (concentration of substrate at which the rate of end-product formation is equal to half the maximum velocity) is higher and the catalytic rate constant is lower than at a normal pH. Furthermore, the plasminogen-streptokinase complex can dissociate entirely at a low pH. Thus, in cardiogenic shock, alterations in blood pH may adversely affect the conversion of plasminogen to plasmin, impairing both intrinsic endothelial cell thromboresistance and thrombolytic efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Procoagulant properties of plasmin and platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous administration of a thrombolytic agent causes in a conversion of plasminogen to plasmin. As with other serine proteases, plasmin is capable of factor XII activation (contact activation), which in turn, activates prekallikrein, factor XI, and high molecular weight kininogen. Plasmin-mediated contact activation can also activate factor VII and platelets. Thus, plasmin generation is capable of enhancing both fibrinolytic and procoagulant activity.",
"   </p>",
"   <p>",
"    Platelet activation can promote thrombus formation directly and can indirectly limit thrombolysis via the release from cytoplasmic granules of plasminogen-activator inhibitor type 1 (PAI-1) and alpha-2-antiplasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/74\">",
"     74",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that failure of thrombolysis with streptokinase is associated with pretreatment levels of PAI-1 greater than 4",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/75\">",
"     75",
"    </a>",
"    ]. Fibrinolysis may also be impaired by the release of one or more proteins that stimulate cells to secrete an inhibitor of fibrinolysis and by supplying factor XIIIa for covalent crosslinking, thereby making the thrombus more resistant to lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In highly pro-inflammatory conditions, endothelial cells may assume a strong thrombin-generating capacity through enhanced constitutive tissue factor expression and activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28297/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24690198\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombolysis, defined as the dissolution of thrombus or, more specifically, the breakdown of fibrin (fibrinolysis), is a critical component of vascular homeostasis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the normal functions of the vascular endothelium is to prevent the initiation and development of non-physiologic thrombi (ie, thrombosis not required for hemostatic regulation). Damaged, disrupted, or \"perturbed\" endothelial cells, can lose their ability to maintain thromboresistance and can promote thrombosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thromboresistant properties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exposure of circulating blood to disrupted or dysfunctional surfaces (as with rupture of an atherosclerotic plaque) initiates a series of complex, yet orderly, steps that give rise to the rapid deposition of platelets, erythrocytes, leukocytes, and insoluble fibrin, producing a mechanical barrier to blood flow. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Thrombogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability of a thrombolytic agent to dissolve an occlusive coronary artery thrombus is determined by several factors. The agent must be delivered to, penetrate, and ultimately infiltrate the thrombus. These functions occur while the agent is provided with an adequate amount of substrate (plasminogen) and an appropriate metabolic environment (neutral pH, calcium concentration) for an enzymatic reaction (conversion of plasminogen to plasmin) to take place.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/1\">",
"      Liu Z, Tan JL, Cohen DM, et al. Mechanical tugging force regulates the size of cell-cell junctions. Proc Natl Acad Sci U S A 2010; 107:9944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/2\">",
"      Piper P, Vane J. The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci 1971; 180:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/3\">",
"      Willis AL, Smith DL, Vigo C, Kluge AF. Effects of prostacyclin and orally active stable mimetic agent RS-93427-007 on basic mechanisms of atherogenesis. Lancet 1986; 2:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/4\">",
"      Gleim S, Kasza Z, Martin K, Hwa J. Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep 2009; 11:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/5\">",
"      Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/6\">",
"      Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/7\">",
"      Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/8\">",
"      Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/9\">",
"      Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998; 98:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/10\">",
"      Miner SE, Al-Hesayen A, Nield LE, et al. Acetylcholine acutely modifies nitric oxide synthase function in the human coronary circulation. Exp Physiol 2010; 95:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/11\">",
"      Kaposzta Z, Baskerville PA, Madge D, et al. L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation 2001; 103:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/12\">",
"      Stein CM, Brown N, Vaughan DE, et al. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol 1998; 32:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/13\">",
"      Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/14\">",
"      Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/15\">",
"      Stern DM, Bank I, Nawroth PP, et al. Self-regulation of procoagulant events on the endothelial cell surface. J Exp Med 1985; 162:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/16\">",
"      Shirk RA, Church FC, Wagner WD. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler Thromb Vasc Biol 1996; 16:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/17\">",
"      Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/18\">",
"      Keane MP, Strieter RM. Chemokine signaling in inflammation. Crit Care Med 2000; 28:N13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/19\">",
"      Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/20\">",
"      Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88:4651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/21\">",
"      Smith WB, Noack L, Khew-Goodall Y, et al. Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 1996; 157:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/22\">",
"      Weiss JM, Cuff CA, Berman JW. TGF-beta downmodulates cytokine-induced monocyte chemoattractant protein (MCP)-1 expression in human endothelial cells. A putative role for TGF-beta in the modulation of TNF receptor expression. Endothelium 1999; 6:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/23\">",
"      Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274:31868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/24\">",
"      Mulligan MS, Jones ML, Vaporciyan AA, et al. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 1993; 151:5666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/25\">",
"      Pugin J, Ulevitch RJ, Tobias PS. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med 1993; 178:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/26\">",
"      Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/27\">",
"      Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/28\">",
"      Ashby DT, Rye KA, Clay MA, et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/29\">",
"      Cockerill GW, Saklatvala J, Ridley SH, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999; 19:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/30\">",
"      Baker PW, Rye KA, Gamble JR, et al. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999; 40:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/31\">",
"      Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/32\">",
"      Xia P, Vadas MA, Rye KA, et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274:33143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/33\">",
"      Sampath R, Kukielka GL, Smith CW, et al. Shear stress-mediated changes in the expression of leukocyte adhesion receptors on human umbilical vein endothelial cells in vitro. Ann Biomed Eng 1995; 23:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/34\">",
"      Mohan S, Mohan N, Valente AJ, Sprague EA. Regulation of low shear flow-induced HAEC VCAM-1 expression and monocyte adhesion. Am J Physiol 1999; 276:C1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/35\">",
"      Inoue N, Ramasamy S, Fukai T, et al. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. Circ Res 1996; 79:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/36\">",
"      Dimmeler S, Hermann C, Galle J, Zeiher AM. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/37\">",
"      Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/38\">",
"      Christopherson KW 2nd, Campbell JJ, Travers JB, Hromas RA. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 2002; 302:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/39\">",
"      Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/40\">",
"      Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/41\">",
"      Cohen RA, Zitnay KM, Haudenschild CC, Cunningham LD. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ Res 1988; 63:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/42\">",
"      Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/43\">",
"      Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83:4533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/44\">",
"      Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/45\">",
"      Stern DM, Drillings M, Nossel HL, et al. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci U S A 1983; 80:4119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/46\">",
"      Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol 1987; 66:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/47\">",
"      Stern DM, Nawroth PP, Kisiel W, et al. The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X. J Biol Chem 1985; 260:6717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/48\">",
"      Yang Z, Arnet U, Bauer E, et al. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction. Role of prostacyclin, nitric oxide, and thromboxane A2. Circulation 1994; 89:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/49\">",
"      Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/50\">",
"      Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/51\">",
"      Fern&aacute;ndez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/52\">",
"      Hatton MW, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/53\">",
"      Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/54\">",
"      Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/55\">",
"      Stabenfeldt SE, Gossett JJ, Barker TH. Building better fibrin knob mimics: an investigation of synthetic fibrin knob peptide structures in solution and their dynamic binding with fibrinogen/fibrin holes. Blood 2010; 116:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/56\">",
"      O'Brien ET 3rd, Falvo MR, Millard D, et al. Ultrathin self-assembled fibrin sheets. Proc Natl Acad Sci U S A 2008; 105:19438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/57\">",
"      Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/58\">",
"      Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/59\">",
"      Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/60\">",
"      Suenson E, L&uuml;tzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 1984; 140:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/61\">",
"      Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 20:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/62\">",
"      Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994; 23:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/63\">",
"      Marder VJ, Soulen RL, Atichartakarn V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/64\">",
"      Theiss W, Wirtzfeld A, Fink U, Maubach P. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983; 34:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/65\">",
"      Marx G. Divalent cations induce protofibril gelation. Am J Hematol 1988; 27:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/66\">",
"      Stewart UA, Bradley MS, Johnson CS Jr, Gabriel DA. Transport of probe molecules through fibrin gels as observed by means of holographic relaxation methods. Biopolymers 1988; 27:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/67\">",
"      Blomb&auml;ck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/68\">",
"      Jones M, Gabriel DA. Influence of the subendothelial basement membrane components on fibrin assembly. Evidence for a fibrin binding site on type IV collagen. J Biol Chem 1988; 263:7043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/69\">",
"      Carr ME Jr, Powers PL. Effect of glycosaminoglycans on thrombin- and atroxin-induced fibrin assembly and structure. Thromb Haemost 1989; 62:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/70\">",
"      Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem 1985; 260:7502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/71\">",
"      Shulman, S, Ferry, JD, Tinoco, I Jr. The conversion of fibrinogen to fibrin. XII. Influence of pH, ionic strength and hexamethylene glycol concentration on the polymerization of fibrinogen. Univ Wis 1952; 42:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/72\">",
"      Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/73\">",
"      Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biol Chem 1980; 255:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/74\">",
"      Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/75\">",
"      Sinkovic A. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 1998; 136:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/76\">",
"      Schafer AI, Maas AK, Ware JA, et al. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/77\">",
"      Greenberg JP, Packham MA, Guccione MA, et al. Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979; 53:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/78\">",
"      Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28297/abstract/79\">",
"      Cuccuini W, Poitevin S, Poitevin G, et al. Tissue factor up-regulation in proinflammatory conditions confers thrombin generation capacity to endothelial colony-forming cells without influencing non-coagulant properties in vitro. J Thromb Haemost 2010; 8:2042.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1490 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28297=[""].join("\n");
var outline_f27_40_28297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24690198\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VASCULAR ENDOTHELIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anatomic considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thromboresistant properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prostacyclin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Plasminogen activators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Plasminogen activator inhibitor-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Heparin-like molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Heparin cofactor II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antithrombin III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Protein C and protein S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tissue factor pathway inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Annexin V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiinflammatory properties of the normal vessel wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endothelial cell function and coronary atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THROMBOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Platelet deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Activation of coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fibrin formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      THROMBOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Plasminogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Plasmin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Determinants of thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hemodynamic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Mechanical factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Thrombus composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Plasminogen activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Procoagulant properties of plasmin and platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24690198\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1490|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/25/14749\" title=\"figure 1\">",
"      Plasmin and thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/2/20525\" title=\"figure 2\">",
"      BP and efficacy of thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/8/32907\" title=\"table 1\">",
"      Endothelial cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/3/33851\" title=\"table 2\">",
"      Components fibrinolytic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=related_link\">",
"      Fibrinolytic markers and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=related_link\">",
"      The coronary microcirculation in disease states",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_40_28298="Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus";
var content_f27_40_28298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Luke F Chen, MBBS, MPH, CIC, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28298/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/40/28298/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/40/28298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic properties of alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for use in treatment of invasive infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus will be reviewed here. Five drugs will be discussed here:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    . Issues related to the role of these agents for treatment of specific infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034132\">",
"    <span class=\"h1\">",
"     DAPTOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is a cyclic lipopeptide that is active against gram-positive organisms including streptococci, enterococci (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci), methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While S. aureus isolates with complete or intermediate resistance to vancomycin have maintained susceptibility to daptomycin, MRSA isolates with increased minimum inhibitory concentrations (MICs) to vancomycin may also exhibit reduced susceptibility to daptomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is FDA-approved for the treatment of complicated skin and skin-structure infections (cSSSI) and for bacteremia with or without right-sided endocarditis due to MRSA and other selected gram-positive pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034159\">",
"    <span class=\"h2\">",
"     Mechanism and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is rapidly bactericidal. Its primary mechanism of action is calcium-dependent depolarization of bacterial cell wall [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Daptomycin has a lipophilic tail, which binds and inserts itself into the bacterial membrane and forms a channel that causes efflux of intracellular potassium with subsequent depolarization of the cell membrane. The antimicrobial activity of daptomycin is concentration-dependent and is associated with a prolonged post-antibiotic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Daptomycin is inactivated by alveolar surfactants, and therefore should not be used for pulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    are not fully understood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/11\">",
"     11",
"    </a>",
"    ]. Daptomycin resistance appears to emerge gradually via multiple steps resulting in a heteroresistant subpopulation with elevated minimum inhibitor concentration (MIC) to daptomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/3\">",
"     3",
"    </a>",
"    ]. Altered cell membrane potential due to changes in cell membrane surface charge has been shown to lead to reduced daptomycin binding to the cell membrane and reduced susceptibility to daptomycin-induced depolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment-emergent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    resistance has been associated with prolonged therapy in MRSA bacteremia and subtherapeutic daptomycin concentrations in bone tissues with retained infected bone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Sporadic, treatment-emergent resistance in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant E. faecium has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034166\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    has poor oral bioavailability and must be administered parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/5\">",
"     5",
"    </a>",
"    ]. Daptomycin rapidly binds to serum albumin (90 to 95 percent) and distributes primarily in the vascular space [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/17\">",
"     17",
"    </a>",
"    ]. The high affinity to serum proteins and a small volume of distribution (0.1",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    prevents the drug from effectively crossing host cell membranes or select tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/17\">",
"     17",
"    </a>",
"    ]. For example, the penetration of daptomycin into lung tissue and infected bone are low (relative to its serum concentration, 9 and 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Daptomycin poorly penetrates into the cerebrospinal fluid, even with meningeal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, reduced tissue penetration may limit the routine use of daptomycin for infections such as osteomyelitis and meningitis, despite case reports of clinical cures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    has a half-life of approximately 8 hours; the drug is primarily excreted unchanged via the kidneys (80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/9,22,23\">",
"     9,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034173\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events reported in a phase III clinical study included constipation, nausea, and injection site reactions (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    administration has been associated with elevations in creatine phosphokinase (CPK) and myopathy. In phase III studies the prevalence of asymptomatic CPK elevation and symptomatic myopathy were 2.8 and 0.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/23\">",
"     23",
"    </a>",
"    ]. Daptomycin has also been associated with rhabdomyolysis in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    -related muscle complications often manifest with muscle pains within one week of starting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Daptomycin should be discontinued if muscle related complications are suspected or identified. Symptoms generally resolve within 2 to 3 days after discontinuation of the drug, although CPK elevations may persist up to 2 weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    -induced eosinophilic pneumonia and chronic pneumonitis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034180\">",
"    <span class=\"h2\">",
"     Pregnancy category B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies using high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    therapy have not revealed any teratogenicity. There are no adequate or well-controlled studies in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034187\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is neither an inducer nor an inhibitor of the hepatic CYP450 system. Concomitant administration of HMG-CoA reductase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    may increase the risk of CPK elevation and myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034194\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of complicated skin and skin structure infections, 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily should be administered. A higher dose (ie, 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily IV) is used in the treatment of bloodstream infections and right-sided endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Because of its concentration-dependent activity, use of higher doses (&gt; 8",
"    <span class=\"nowrap\">",
"     mg/kg/d)",
"    </span>",
"    have been reported but are not yet FDA-approved. The dosing interval should be increased to every 48 hours in patients with severe renal impairment (creatinine clearance of &lt;30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    In patients receiving intermittent hemodialysis, the dose should be given after hemodialysis whenever possible. No adjustment is required for mild to moderate hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13034201\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to monitoring for clinical response, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    therapy should undergo a baseline CPK measurement followed by weekly monitoring. Patients should also be evaluated regularly for clinical evidence of myopathy. The drug should be discontinued in patients with symptomatic myopathy and CPK &ge;5 times the upper limit of normal (ULN) or in asymptomatic patients with CPK &ge;10 times ULN.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    minimum concentration (Cmin) &ge;24.3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    has been associated with an increased probability of a CPK elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/30\">",
"     30",
"    </a>",
"    ]. Routine Cmin monitoring is not practical due to availability, though it may be warranted in the setting of CPK elevation for circumstances in which use of daptomycin is imperative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LINEZOLID",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is a synthetic oxazolidinone with in vitro activity against a variety of gram-positive organisms including streptococci, enterococci (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci), coagulase-negative staphylococci, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The FDA has approved linezolid for the treatment of nosocomial pneumonia and complicated skin and soft tissue structure infections (cSSSI), including those due to MRSA and vancomycin-resistant Enterococcus faecium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, linezolid is not approved for the treatment of catheter-related bloodstream infections (CR-BSIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism, resistance, and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is bacteriostatic against most organisms. It binds to the 50S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/33,38\">",
"     33,38",
"    </a>",
"    ]. In addition, linezolid suppresses the production of bacterial toxins such as Panton-Valentine Leukocidin (PVL), alpha-hemolysin, and toxic-shock syndrome toxin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The antimicrobial activity of linezolid is best predicted by the ratio of the 24 hour area under the time-concentration curve (AUC) to minimum inhibitory concentration (MIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It displays moderate post-antibiotic effects against S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    may fail to bind its bacterial target site in the presence of single point mutations in the bacterial 23S rRNA of the 50S subunit. While enterococci and S. aureus with in vitro resistance to linezolid have been reported, in vitro resistance in S. aureus is infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Mutations in 23S rRNA that confer resistance to linezolid can produce cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    , which also bind to the same 23S rRNA domain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    approaches 100 percent following oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/48\">",
"     48",
"    </a>",
"    ]. Linezolid binds poorly to serum proteins (31 percent), and thus it penetrates well into most body compartments (including bone, alveoli and the cerebrospinal space) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/48\">",
"     48",
"    </a>",
"    ]. As a result, linezolid has a volume of distribution that is similar to total body water (30 to 50 L). The overall tissue distribution of linezolid is stable and is not adversely affected by sepsis or peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/43,49-52\">",
"     43,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    does not interact with the cytochrome P450 oxidative system but rather undergoes hepatic oxidative metabolism into two inactive metabolites. Its metabolites are eliminated predominantly in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/43\">",
"     43",
"    </a>",
"    ]. The elimination half-life of linezolid is 5 to 7 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    in phase III clinical trials were mild symptoms of diarrhea (4.3 percent), nausea (3.4 percent), headache (2.2 percent), and altered taste (1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/53\">",
"     53",
"    </a>",
"    ]. Other important adverse effects related to linezolid use include myelosuppression, optic neuropathy, peripheral neuropathy, and lactic acidosis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    -induced thrombocytopenia is the most frequently observed blood dyscrasia with linezolid (occurring in up to one-third of recipients), although all blood cell lineages may be depressed with prolonged and high cumulative doses of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Risk factors for linezolid-induced myelosuppression include renal impairment, low baseline blood cell counts, and duration of therapy &gt;14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Administration of pyridoxine (B6) successfully reversed linezolid-induced thrombocytopenia in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/61\">",
"     61",
"    </a>",
"    ], but did not prevent myelosuppression for treatment exceeding two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has been associated with optic and peripheral neuropathy in some studies, generally following several weeks of use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Decreased visual acuity, development of scotomas, and diminished color perception have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/64\">",
"     64",
"    </a>",
"    ]. The pathogenesis of optic neuropathy is uncertain, although the clinical manifestations mirror the findings observed in the setting of ocular neuropathy due to nutritional deficiency and mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitochondrial impairment may account for two other uncommon adverse effects: peripheral neuropathy and lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    induced peripheral neuropathy usually manifests as a \"glove and stocking\" sensory impairment with a sensory-motor axonal pattern on nerve conduction studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/63,71\">",
"     63,71",
"    </a>",
"    ]. This adverse effect is time- and dose-dependent with the use of linezolid and may not resolve after discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    -related lactic acidosis have been reported. In many patients, lactic acidosis occurred after 40 to 50 days on linezolid therapy and was associated with nausea, vomiting, or generalized weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/73\">",
"     73",
"    </a>",
"    ]. Discontinuation of linezolid usually resulted in normalization of lactic acidemia. It has been postulated that linezolid cross-interacts with human mitochondrial 16S RNA because of its resemblance to bacterial 23S rRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy category C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA lists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    as a category C drug, since some animal studies showed decreased fetal body weights and increased incidence of fusion of costal cartilages. There are no adequate and well-controlled studies in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is a weak inhibitor of monoamine oxidase (MAO) and can precipitate serotonin toxicity when coadministered with non-selective MAO inhibitors, selective serotonin-reuptake inhibitors (SSRIs), or serotonin norepinephrine reuptake Inhibitors (SNRIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/35,76,77\">",
"     35,76,77",
"    </a>",
"    ]. Most case reports of linezolid-induced serotonin syndrome occurred within one week of starting linezolid therapy in conjunction with the administration of an SSRI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/78\">",
"     78",
"    </a>",
"    ]. Deaths from this interaction have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    -related serotonin toxicity can usually be managed by discontinuing linezolid, the",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs,",
"    </span>",
"    or both. Some authors have reported successful treatment of serotonin toxicity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/79\">",
"     79",
"    </a>",
"    ]. The median time to resolution of symptoms is usually 48 hours from the time of adjusting medications.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    with MAO inhibitors or",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs",
"    </span>",
"    should be avoided. If they are coadministered, close monitoring for signs and symptoms of serotonin syndrome is critical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    is 600 mg intravenously or orally twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/80\">",
"     80",
"    </a>",
"    ]. Linezolid does not require dosing adjustment in hepatic or renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/81\">",
"     81",
"    </a>",
"    ]. However, high-flux exchange membranes can remove up to one-third of the serum level of linezolid during hemodialysis. For patients on hemodialysis, one of the two daily doses should be given after dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to monitoring clinical response, weekly complete blood counts should be monitored for patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    therapy for more than 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/55\">",
"     55",
"    </a>",
"    ]. Serum concentration monitoring of linezolid is not required in routine practice. Some favor evaluating serum lactate in the setting of nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced serum bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032953\">",
"    <span class=\"h1\">",
"     CEFTAROLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is a parenteral cephalosporin with antimicrobial activity against S. aureus (including methicillin-resistant S. aureus [MRSA],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -intermediate S. aureus [VISA], and vancomycin-resistant S. aureus [VRSA]), Enterococcus faecalis (but not Enterococcus faecium), and Streptococcus pneumoniae. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, ceftaroline has in vitro activity against gram-negative respiratory pathogens, such as Moraxella catarrhalis and Haemophilus influenzae (including beta-lactamase-positive strains). Its in vitro activity against gram-negative organisms is comparable to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is approved by the US Food and Drug Administration for treatment of complicated skin and skin-structure infections (cSSSI), including those caused by MRSA, and treatment of community-acquired bacterial pneumonia (not including those caused by MRSA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032961\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    binds to penicillin-binding proteins (PBPs). It has enhanced affinity for PBP subclasses 1, 2, and 3; in addition, it has activity against MRSA (PBP 2A) and multidrug-resistant S. pneumoniae (PBP 1a, 2b and 2x).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032969\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inactive prodrug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    fosamil is administered by intravenous infusion and rapidly undergoes biotransformation to ceftaroline. Ceftaroline then follows a two-compartment pharmacokinetic model and is eliminated primarily by renal excretion with a half-life of approximately 2.5 hours.",
"   </p>",
"   <p>",
"    Tissue penetration is similar to that of other cephalosporins and beta-lactams; less than 20 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    is bound to plasma proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/83\">",
"     83",
"    </a>",
"    ]. Animal studies have suggested good bone and joint penetration and achieved significant reductions of MRSA colony counts compared with controls; colony reductions were comparable to those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/84\">",
"     84",
"    </a>",
"    ]. Cerebrospinal fluid (CSF) penetration of ceftaroline into inflamed meninges was 15 percent in rabbit meningitis models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Time above the minimum inhibitory concentration is the pharmacodynamic parameter that best predicts efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    . Ceftaroline has a brief post-antibiotic effect (PAE) following a single infusion, which may last as long as 7.2 hours for S. aureus based on in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032977\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    is 600 mg intravenously twice daily; dose adjustment is warranted for patients with renal impairment. For patients with creatinine clearance &gt;30 to &le;50, dosing is 400 mg IV (over 1 hour) every 12 hours; for patients with creatinine clearance &ge;15 to &le;30, dosing is 300 mg IV (over 1 hour) every 12 hours. For patients with end-stage renal disease, including those undergoing hemodialysis, dosing is 200 mg IV (over 1 hour) every 12 hours. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032985\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is generally well tolerated. The most common adverse events in phase III studies were diarrhea (4 percent), headache (3 percent), and insomnia (3 percent). The incidence of these events was not higher than those in the comparator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/87\">",
"     87",
"    </a>",
"    ]. The rate of drug discontinuation was similar between the groups (4 to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/87\">",
"     87",
"    </a>",
"    ]. A seroconversion of direct Coombs&rsquo; test (in the absence of hemolytic anemia) has been reported with ceftaroline in up to 10 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13032993\">",
"    <span class=\"h2\">",
"     Pregnancy category B",
"    </span>",
"    &nbsp;&mdash;&nbsp;No well-controlled studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    in pregnant women have been performed. There is no evidence of teratogenic effects in animal studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13033001\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical drug interaction studies have been conducted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    . In the clinical studies including patients taking concurrent drugs known to be cytochrome P450 enzyme inducers, inhibitors, or substrates, no clinically relevant differences in ceftaroline exposure were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TIGECYCLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is a glycylcycline antibiotic with in vitro activities against a variety of gram-positive organisms including methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and E. faecalis (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant variants) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. In addition, tigecycline exhibits activity against a broad spectrum of gram-negative and anaerobic organisms. Notable exceptions are the lack of activity against Pseudomonas spp and Proteus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/93\">",
"     93",
"    </a>",
"    ]. Tigecycline is FDA-approved for complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections, and community-acquired pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mechanism and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    inhibits bacterial protein synthesis by acting on the 30S ribosomal subunit and preventing amino acids from becoming incorporated into elongating peptide chains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Tigecycline is bacteriostatic and has prolonged post-antibiotic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. It appears to have both time- and concentration-dependent characteristics, and its antimicrobial effect correlates well with the AUC achieved by the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudomonas spp and Proteus spp have intrinsic resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    . The reduced susceptibility to tigecycline in gram-negative organisms is largely mediated via multi-drug efflux pumps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    has poor bioavailability from the gastrointestinal tract and requires intravenous administration. Tigecycline binds moderately with plasma proteins (68 percent), distributes extensively into tissues and (consequently) has low serum drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Tissue drug concentrations in humans vary widely. Tigecycline adequately penetrates into the alveolar epithelial cells and the biliary tract, but entry into bone and synovial membranes is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. CSF penetration through uninflamed meninges is also minimal, and it is uncertain whether tigecycline is adequate for reliable treatment of meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unchanged",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    is eliminated by glucuronidation and subsequent excretion via the biliary tract. Less than 30 percent of the drug is excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse drug effects reported in phase III studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    were mild nausea and vomiting (approximately 30 and 19 percent of patients, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/106\">",
"     106",
"    </a>",
"    ]. Tigecycline, like its relatives in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    family, carries the potential for discoloring dentition and fetal teratogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/93\">",
"     93",
"    </a>",
"    ]. Animal studies showed that tigecycline crossed the placenta and was detected in fetal tissue, including fetal bony structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy category D",
"    </span>",
"    &nbsp;&mdash;&nbsp;An animal study also showed delayed bone and increased incidence of fetal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/107\">",
"     107",
"    </a>",
"    ]. Therefore, it should not be used in pregnancy unless the potential benefit clearly outweighs the potential risk to the mother or the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    may decrease the elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/108\">",
"     108",
"    </a>",
"    ]. Patients receiving anticoagulation with warfarin should have the INR monitored closely with adjustment in dosing as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    consists of a single loading dose of 100 mg IV followed by 50 mg IV every 12 hours. Maintenance doses should be reduced by one-half in patients with severe hepatic dysfunction (Child-Pugh C). No dosage adjustment is required for patients with renal impairment or hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is generally well tolerated and does not require clinical or therapeutic drug monitoring. Patients with significant hepatic dysfunction should have liver function tests taken at the baseline and regularly throughout the treatment with tigecycline. Patients receiving anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should have the INR monitored closely with adjustment in dosing as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     QUINUPRISTIN-DALFOPRISTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    (QD) is a combination of two semi-synthetic streptogramins in a ratio of 30:70 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/109\">",
"     109",
"    </a>",
"    ]. QD has activity in vitro against gram-positive organisms including methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). QD is active against Enterococcus faecium but not E. faecalis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mechanism and pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    binds to two sequential sites on the 50S subunit of the bacterial ribosome, resulting in a conformational change in the ribosome and preventing protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/111\">",
"     111",
"    </a>",
"    ]. QD is a concentration-dependent bactericidal antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/112\">",
"     112",
"    </a>",
"    ]. Staphylococcal isolates constitutively expressing macrolide-lincosamide-streptogramin B (MLS B) resistance (eg, erm A or erm C) may be resistant to the quinupristin component of QD. In such cases, the activity of QD may be significantly altered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    (QD) is a mixture of two synergistic streptogramins; each component of QD is associated with different mechanisms of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/115\">",
"     115",
"    </a>",
"    ]. Resistant staphylococci are more likely to have resistance to the dalfopristin component, due to genes encoding acetyltransferases (vatA, vatB, and vatC) or efflux pumps (vgaA and vgaB) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/116-119\">",
"     116-119",
"    </a>",
"    ]. Resistance to the quinupristin component occurs as a result of production of ribosomal methylases encoded by erm genes, or the macrolide-lincosamide-streptogramin B (MLSB) phenotype (which also confers cross resistance to macrolides and lincosamides).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two components of QD have different affinity for serum protein: approximately 30 percent of quinupristin and 50 percent of dalfopristin are protein bound [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/111\">",
"     111",
"    </a>",
"    ]. After IV administration,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    penetrates readily into intraabdominal organs such as kidneys, liver, and the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/120\">",
"     120",
"    </a>",
"    ]. Penetration of QD into other tissues varies significantly. Studies on lung tissue penetration have shown variable results; clinical studies appear to demonstrate efficacy for treatment of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/121\">",
"     121",
"    </a>",
"    ]. Minimal data exist regarding penetration of QD into bones and joints; limited clinical data appear to demonstrate efficacy against infections at these sites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/122\">",
"     122",
"    </a>",
"    ]. Quinupristin-dalfopristin penetrates poorly into the central nervous system (CNS) and should not be used as monotherapy for CNS infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QD undergoes hepatic metabolism to produce several active metabolites that are primarily eliminated in the feces [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;QD frequently causes infusion site pain and edema (50 to 75 percent) and occasionally thrombophlebitis (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/123\">",
"     123",
"    </a>",
"    ]. Other adverse effects associated with QD include nausea and myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. The severity of these adverse effects in clinical trials prompted discontinuation of treatment with QD in 15 to 19 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QD is associated with increased levels of total and conjugated bilirubin; increases &gt;5 x ULN occurred in approximately 30 percent of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/126\">",
"     126",
"    </a>",
"    ]. The clinical importance of the hyperbilirubinemia is uncertain, as many patients enrolled in studies had high baseline bilirubin levels. Transient elevations in transaminases and alkaline phosphatase (ALP) were also noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pregnancy category B",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenic effects in animal studies. There are no adequate or well-controlled studies with QD in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    is a potent inhibitor of the CYP3A4 isoenzyme and may increase the pharmacologic action of other medications that are metabolized via this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/123\">",
"     123",
"    </a>",
"    ]. For example, co-administration with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , antiretroviral agents, calcium channel blockers, statins, and anticonvulsants can result in significant changes in the serum level and half-life of these drugs. Coadministration of QD with any agent that is metabolized via this enzymatic pathway should be closely monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of QD for MRSA soft tissue infections is 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours intravenously; VRE (faecium) infections are treated with 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours.",
"   </p>",
"   <p>",
"    QD should be infused through a central venous catheter over 1 hour due to the substantial risk of local pain and thrombophlebitis. The concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    does not alleviate venous pain or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/112\">",
"     112",
"    </a>",
"    ]. If irritation occurs after peripheral administration, interventions may include changing the infusion volume or the infusion site, or infusing by a peripherally inserted central catheter (PICC) or a central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/40/28298/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose adjustment is not necessary for patients with renal impairment, as QD is not removed by hemodialysis. Dose adjustment of QD is not required for mild to moderate hepatic impairment (Childs-Pugh class A &amp; B). There are insufficient data to recommend dose adjustment of QD in patients with severe hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver function tests should be performed regularly to assess for elevations in bilirubin and transaminases. Moreover, concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    and other agents metabolized via cytochrome P450 pathway requires caution and monitoring of these agents where possible (eg, measuring serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      is a bactericidal cyclic lipopeptide with lipophilic tail that inserts itself into the bacterial membrane and forms a channel causing efflux of intracellular potassium, with subsequent depolarization of the cell membrane. Daptomycin administration has been associated with myopathy; weekly creatine phosphokinase monitoring should be performed for prolonged administration. (See",
"      <a class=\"local\" href=\"#H13034132\">",
"       'Daptomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      is a bacteriostatic oxazolidinone that binds to the 50S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis. Important adverse effects related to linezolid use include myelosuppression, optic neuropathy, peripheral neuropathy, lactic acidosis, and serotonin syndrome. Weekly complete blood count monitoring should be performed for prolonged administration (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Linezolid'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"       Ceftaroline",
"      </a>",
"      is a parenteral cephalosporin with activity against methicillin-resistant S. aureus (MRSA). It is well-tolerated and is approved for use in community-acquired pneumonia and for the treatment of complex skin and soft-tissue infections, including MRSA. (See",
"      <a class=\"local\" href=\"#H13032953\">",
"       'Ceftaroline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       Tigecycline",
"      </a>",
"      is a bacteriostatic glycylcycline that acts on the 30S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis. It is active against resistant gram-positive organisms as well as gram-negatives and anaerobes, but is NOT active Pseudomonas or Proteus spp. The most common adverse drug effects are mild nausea and vomiting. Tigecycline is generally well tolerated and does not require clinical or therapeutic drug monitoring. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Tigecycline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Quinupristin/dalfopristin",
"      </span>",
"      is a bactericidal combination of two semi-synthetic streptogramins that bind to two sequential sites on the 50S subunit of the bacterial ribosome, resulting in a conformational change in the ribosome and preventing protein synthesis. It should be infused through a central venous catheter due to the substantial risk of local pain and thrombophlebitis. It is associated with conjugated hyperbilirubinemia, and liver function test monitoring should be performed. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Quinupristin-dalfopristin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/1\">",
"      Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/2\">",
"      Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/3\">",
"      Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/4\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     Cubist. Cubicin - Prescribing Information. CUBIST 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/6\">",
"      Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/7\">",
"      Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/8\">",
"      Braga PC, Ricci D, Dal Sasso M. Daptomycin morphostructural damage in Bacillus cereus visualized by atomic force microscopy. J Chemother 2002; 14:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/9\">",
"      Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/10\">",
"      Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/11\">",
"      Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/12\">",
"      Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/13\">",
"      Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/14\">",
"      Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/15\">",
"      Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/16\">",
"      King ST, Usery JB, Holloway K, et al. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. J Antimicrob Chemother 2011; 66:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/17\">",
"      Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/18\">",
"      Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/19\">",
"      Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/20\">",
"      Burns CA. Long-term use of daptomycin for MRSA osteomyelitis and joint infection. Scand J Infect Dis 2008; 40:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/21\">",
"      Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/22\">",
"      Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/23\">",
"      Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42:e108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/24\">",
"      Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/25\">",
"      Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/26\">",
"      Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004; 150:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/27\">",
"      Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother 2004; 38:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/28\">",
"      Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/29\">",
"      Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010; 50:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/30\">",
"      Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/31\">",
"      Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/32\">",
"      Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/33\">",
"      Wootton M, Howe RA, Walsh TR, et al. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother 2002; 50:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/34\">",
"      Ballow CH, Jones RN, Biedenbach DJ, North American ZAPS Research Group. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43:75.",
"     </a>",
"    </li>",
"    <li>",
"     Zyvox (linezolid) brochure for the anti-infective drug products advisory committee meeting. Pharmacia, Upjohn 2000.",
"    </li>",
"    <li>",
"     Food and Drug Administration (FDA). FDA Approves Zyvox, The First Antimicrobial Drug In A New Class. In: FDA Talk Paper, Rockville, MD 2000.",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for healthcare professionals: Linezolid (marketed as Zyvox). Available at: file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085249.htm (Accessed January 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/38\">",
"      Champney WS, Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 2002; 44:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/39\">",
"      Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/40\">",
"      Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/41\">",
"      Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/42\">",
"      Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/43\">",
"      MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl 2:ii17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/44\">",
"      Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/45\">",
"      Besier S, Ludwig A, Zander J, et al. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 2008; 52:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/46\">",
"      Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/47\">",
"      Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/48\">",
"      Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/49\">",
"      Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007; 60:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/50\">",
"      Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/51\">",
"      Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/52\">",
"      Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/53\">",
"      French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 Suppl 2:ii45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/54\">",
"      Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/55\">",
"      Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/56\">",
"      Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/57\">",
"      Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/58\">",
"      Mateu de Antonio J, Grau S, Morales-Molina JA, Mar&iacute;n-Casino M. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis 2006; 42:1500; author reply 1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/59\">",
"      Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/60\">",
"      Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/61\">",
"      Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/62\">",
"      Plachouras D, Giannitsioti E, Athanassia S, et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43:e89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/63\">",
"      Legout L, Senneville E, Gomel JJ, et al. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/64\">",
"      Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/65\">",
"      Chao CC, Sun HY, Chang YC, Hsieh ST. Painful neuropathy with skin denervation after prolonged use of linezolid. J Neurol Neurosurg Psychiatry 2008; 79:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/66\">",
"      Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/67\">",
"      Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/68\">",
"      De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/69\">",
"      Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003; 348:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/70\">",
"      Javaheri M, Khurana RN, O'hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007; 91:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/71\">",
"      Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/72\">",
"      Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/73\">",
"      Wiener M, Guo Y, Patel G, Fries BC. Lactic acidosis after treatment with linezolid. Infection 2007; 35:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/74\">",
"      Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zyvox label. Available at: file://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf (Accessed January 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/76\">",
"      Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001; 41:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/77\">",
"      Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/78\">",
"      Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/79\">",
"      Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/80\">",
"      Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/81\">",
"      Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/82\">",
"      Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271.",
"     </a>",
"    </li>",
"    <li>",
"     Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/84\">",
"      Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010; 65:1749.",
"     </a>",
"    </li>",
"    <li>",
"     Cottanoud P. et al. Ceftaroline fosamil against penicillin-sensitive and penicillin-resistant Streptococcus pneumoniae in an experimental meningitis model. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/86\">",
"      Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/87\">",
"      DiMondi VP, Drew RH, Chen LF. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy. Expert Rev Anti Infect Ther 2011; 9:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/88\">",
"      Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011; 66 Suppl 3:iii11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/89\">",
"      Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/90\">",
"      Cercenado E, Cercenado S, G&oacute;mez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/91\">",
"      Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/92\">",
"      Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45 Suppl 3:S184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/93\">",
"      Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/94\">",
"      Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20:219S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/95\">",
"      Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/96\">",
"      Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/97\">",
"      Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/98\">",
"      Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5:S303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/99\">",
"      Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/100\">",
"      Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 28:1079.",
"     </a>",
"    </li>",
"    <li>",
"     Tombs, N. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Francisco 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/102\">",
"      Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/103\">",
"      Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.",
"     </a>",
"    </li>",
"    <li>",
"     Fang, G, Weiss, W, Scheld, W. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Toronto 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/105\">",
"      Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/106\">",
"      Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     Wyeth. Tygacil - Prescribing Information. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/108\">",
"      Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5:S354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/109\">",
"      Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother 1998; 42:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/110\">",
"      Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/111\">",
"      Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001; 23:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/112\">",
"      Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/113\">",
"      Schmitz FJ, Witte W, Werner G, et al. Characterization of the translational attenuator of 20 methicillin-resistant, quinupristin/dalfopristin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2001; 48:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/114\">",
"      Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl A:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/115\">",
"      Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/116\">",
"      Werner G, Klare I, Heier H, et al. Quinupristin/dalfopristin-resistant enterococci of the satA (vatD) and satG (vatE) genotypes from different ecological origins in Germany. Microb Drug Resist 2000; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/117\">",
"      Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/118\">",
"      Karanika M, Prati A, Kiritsi M, et al. Reduced susceptibility to quinupristin/dalfopristin in Enterococcus faecium in Greece without prior exposure to the agent. Int J Antimicrob Agents 2008; 31:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/119\">",
"      El Solh N, Allignet J. Staphylococcal resistance to streptogramins and related antibiotics. Drug Resist Updat 1998; 1:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/120\">",
"      Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39 Suppl A:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/121\">",
"      Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/122\">",
"      Summers M, Misenhimer GR, Antony SJ. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. South Med J 2001; 94:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/123\">",
"      Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44 Suppl A:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/124\">",
"      Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/40/28298/abstract/125\">",
"      Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration (FDA). Synercid I.V. - Final Product Labeling. 1999.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 466 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28298=[""].join("\n");
var outline_f27_40_28298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13034132\">",
"      DAPTOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034159\">",
"      Mechanism and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034166\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034173\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034180\">",
"      Pregnancy category B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034187\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034194\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13034201\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LINEZOLID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism, resistance, and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy category C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13032953\">",
"      CEFTAROLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13032961\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13032969\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13032977\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13032985\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13032993\">",
"      Pregnancy category B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13033001\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TIGECYCLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mechanism and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy category D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      QUINUPRISTIN-DALFOPRISTIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mechanism and pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pregnancy category B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_40_28299="Cognit behav intervent fatigue";
var content_f27_40_28299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of cognitive-behavioral interventions to assist patients with fatigue during cancer therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Self-care management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listen to a guided imagery tape daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eat calorie and protein-dense foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Engage in low-impact exercise daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take brief naps early in the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Information, decision-making, and problem solving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess family and social resources and ask for help with daily tasks if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teach side effects of chemotherapy and when to anticipate the nadir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prioritize daily activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Communication with health care providers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell the doctor if you have no energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell the doctor if you feel so exhausted you cannot move",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell the doctor if you are unable to perform usual daily activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Counseling and support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage verbalization of how fatigue has altered lifestyle and has affected emotional well-being",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Given C, et al. J Clin Oncol 2004; 22:507.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28299=[""].join("\n");
var outline_f27_40_28299=null;
var title_f27_40_28300="Small bowel tumor types";
var content_f27_40_28300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of small bowel tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Adenoma",
"       </td>",
"       <td>",
"        Familial adenomatous polyposis",
"       </td>",
"       <td>",
"        Duodenum; ampullary",
"       </td>",
"       <td>",
"        Obstruction; bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Leiomyoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Obstruction; bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Lipoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Obstruction; bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Fibroma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Obstruction; asymptomatic mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hemangioma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Carcinoma",
"       </td>",
"       <td>",
"        Celiac disease; Crohn's disease",
"       </td>",
"       <td>",
"        Jejunum/ileum for Celiac disease; ileum for Crohn's disease",
"       </td>",
"       <td>",
"        Obstruction; bleeding; mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Carcinoid",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Ileum",
"       </td>",
"       <td>",
"        Often asymptomatic; obstruction; carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Lymphoma",
"       </td>",
"       <td>",
"        Celiac disease; autoimmune disease; immunosuppression",
"       </td>",
"       <td>",
"        Ileum",
"       </td>",
"       <td>",
"        Fatigue; weight loss; pain; obstruction; mass; bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sarcoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Jejunum, ileum; Meckel's",
"       </td>",
"       <td>",
"        Obstruction; pain; bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Neuroendocrine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Distal small bowel",
"       </td>",
"       <td>",
"        Mass; hormone-specific symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Metastatic",
"       </td>",
"       <td>",
"        Melanoma; breast; lung; ovary; colon; cervical cancer",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Obstruction; bleeding",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28300=[""].join("\n");
var outline_f27_40_28300=null;
var title_f27_40_28301="Primary closure off-midline for intergluteral pilonidal disease";
var content_f27_40_28301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary closure off-midline for intergluteral pilonidal disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Following an excision of pilonidal disease, if a primary wound closure is performed, the optimal location of the incision is off-midline (lateral).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28301=[""].join("\n");
var outline_f27_40_28301=null;
var title_f27_40_28302="Upper airway obstruction";
var content_f27_40_28302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Importance of the degree of upper airway obstrucion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Volume (as liters [L] from total lung capacity [TLC]) is plotted against inspiratory and expiratory flows. The blue line (C) is the control effort; the numbers refer to the orifice diameters. Lesions must narrow the tracheal lumen to less than&nbsp;8 mm before abnormalities can be detected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Miller RD, Hyatt RE, Mayo Clin Proc 1969; 44:145.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28302=[""].join("\n");
var outline_f27_40_28302=null;
var title_f27_40_28303="Spondylolysis 2";
var content_f27_40_28303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spondylolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spondylolysis refers to a defect in the pars interarticularis (a bone connecting one facet joint to another).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeArt. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_40_28303=[""].join("\n");
var outline_f27_40_28303=null;
